

Progress of the anti-obesity of Berberine

Yue Kong¹, Haokun Yang², Rong Nie¹, Xuxiang Zhang¹, Hongtao Zhang^{3,*} & Xin Nian^{1,4,*}

Abstract:

Obesity is defined as the excessive accumulation or abnormal distribution of body fat. According to data from World Obesity Atlas 2024, the increase in prevalence of obesity has become a major worldwide health problem in adults as well as among children and adolescents. Although an increasing number of drugs have been approved for the treatment of obesity in recent years, many of these drugs have inevitable side effects which have increased the demand for new safe, accessible and effective drugs for obesity and prompt interest in natural products. Berberine (BBR) and its metabolites, known for their multiple pharmacological effects. Recent studies have emphatically highlighted the anti-obesity benefits of BBR and the underlying mechanisms have been gradually elucidated. However, its clinical application is limited by poor oral absorption and low bioavailability. Based on this, this review summarizes current research on the anti-obesity effects of BBR and its metabolites, including advancements in clinical trial results, understanding potential molecular mechanisms and absorption and bioavailability. As a natural compound derived from plants, BBR holds potential as an alternative approach for managing obesity.

Keywords: Berberine, obesity, metabolites/derivatives, molecular mechanism, natural plants, therapies.

1. Introduction

As we known, obesity is a global problem. With over 2 billion people being

¹ Department of Endocrinology, The First Affiliated Hospital of Kunming Medical University, Kunming, China

² Kunming Medical University, Kunming, China

³ Hangzhou CytoCan Biotech, Hangzhou, 310029, China.

⁴ Lead contact

*Corresponding author: Xin Nian and Hongtao Zhang

*Correspondence: nianxinkm@hotmail.com(X.N.), zhanghongtao@cytocan.com (H.T.Z.)

overweight (BMI ≥ 25 kg/m²), of these about 600 million people are having obesity (BMI ≥ 30 kg/m²)^[1]. Of course, if the Asia-Pacific classification of obesity recommended by the World Health Organization (WHO) (overweight: BMI ≥ 23 kg/m², obesity: BMI ≥ 25 kg/m²) was applied, no doubt about that the actual number of obesity will be much higher. Most of these people are living in emerging economies (BRICS countries) and in rapidly developing countries of Asia, Africa, and South America^[2]. According to the specific data from World Obesity Atlas 2024, there were over 800 million adults living with obesity worldwide in 2020 and current trends predict a prevalence of over 1.5 billion in 2035^[3]. Above these evidences, it suggest that obesity has become a major public health problem in the global scale.

Obesity is widely recognized as a complex and multifactorial disease. Pathophysiology of obesity primarily involves out of balance in energy homeostasis and metabolic adaptation, hormonal regulation, neural control, inflammation and immune responses, molecular mechanisms (genetic factors and epigenetic modifications), gut microbiome. Based on this, the incidence, prognosis and treatment effect of obesity itself and various complications caused by obesity are showing a bad situation^{[4][5][6][7][8]}. Currently recommended therapies with evidence-based support in obesity mainly are lifestyle intervention^[9], pharmacotherapy^[10] and bariatric surgery^{[11][12]}.

Lifestyle intervention, known as diet, exercise or behavior therapy, is the recommended initial therapy for improving weight and obesity-related comorbidities in patients with obesity. However, most studies have shown that lifestyle intervention has the disadvantages of poor patient compliance, unreasonable intervention measures, poor clinical effect of weight loss and high risk of weight regain^{[13][14][15]}. For many obese patients, anti-obesity drugs remain the first-line treatment. Anti-obesity drugs are approved in patients with a BMI ≥ 27 kg/m² at least one obesity-related comorbidity or in patients with a BMI ≥ 30 kg/m². Currently approved anti-obesity medications include naltrexone/bupropion, orlistat, liraglutide, semaglutide, tirzepatide and phentermine/topiramate. However, the clinical effect and safety issues of current anti-obesity drugs have brought great challenges to the treatment of obesity


^[5]. For instance, amphetamines and phentermine may lead to serious cardiovascular events, such as arrhythmias and increased blood pressure. Orlistat, which inhibits fat absorption, can cause gastrointestinal issues like steatorrhea (fatty stools) and constipation. In rare cases, these medications have been linked to sudden death ^[16]. In addition, aforementioned drugs including naltrexone/bupropion, orlistat and phentermine/topiramate also were reported that have kidney injury and induce kidney disease^{[17][18][19][20][21]}. GLP-1RAs, new weight loss therapeutics, are often only used on a short-term basis mainly due to high costs and adverse side effects. According to existing research results, most side effects of GLP-1RAs commonly involve gastrointestinal symptoms, pancreatic safety (pancreatitis and pancreatic cancer), thyroid cancer, gallbladder events and injection-site and allergic reactions ^{[22] [23] [24] [25]}. Bariatric surgery alters gastrointestinal anatomy impacting food intake and/or nutrient absorption, which currently targeting patients with BMI $\geq 40\text{kg/m}^2$ or BMI $\geq 35\text{kg/m}^2$ and a comorbidity or failed medical treatment^{[25][26][27][28]}. However, bariatric surgery has limited use due to perceived invasiveness, high cost and postoperative adverse events, including negatively affect bone health, dumping syndrome, VD deficiency, postoperative pain, nausea or vomiting, hypostatic pneumonia, deep venous thrombosis (DVT), pulmonary embolism, stress ulcers ^{[29] [30] [31] [32] [33] [34] [35] [36] [37]}.

The inevitable side effects of aforementioned current obesity therapeutics have increased the demand for new treatments and prompt interest in natural products.

Coptidis Rhizoma (the rhizome of *Coptis chinensis*), commonly known as Huang Lian in China, Ouren in Japan and Hwang-Ryun in Korea, is notable for its diverse alkaloid content ^[38]. From the n-butanol (BuOH) fraction of the methanol (MeOH) extract of Coptidis Rhizoma, several active constituents including BBR (figure 1), epiberberine, coptisine, palmatine and magnoflorine have been isolated, and BBR is the most predominant and attractive component ^[39]. BBR is also found in various medicinal plants such as *Berberis aristata*, *B. petiolaris*, *B. aquifolium*, *B. vulgaris*, *B. thunbergia* and many others ^[40]. The four major metabolites of BBR are berberrubine

(M1), thalifendine (M2), demethyleneberberine (M3), and jatrorrhizine (M4) ^[41].

Figure 1 Chemical Construction of BBR



BBR has been used as an over-the-counter drug in China to treat diarrhea caused by bacteria for more than 70 years, shown very good safety profiles ^[42]. In addition, BBR has other various pharmacological and biological effects, particularly the context of obesity management has received much attention in recent years ^{[38] [42] [43]}. A large number of researches have consistently shown that BBR and its derivatives have favourable clinical effects and safety in the treatment of obesity and related complications. From a mechanistic point of view, Poullos et al. summarized the beneficial effects of the most important phytochemicals that are represented by BBR against obesity. Mechanisms of action include inhibition of adipocyte differentiation, browning of the white adipose tissue (WAT), inhibition of enzymes such as lipase and amylase, suppression of inflammation, improvement of the gut microbiota, and downregulation of obesity-inducing genes ^[44]. In clinical studies, oral administration is the predominant method for BBR delivery, with the primary site for absorption and metabolism being the intestine ^[45]. However, the absolute bioavailability of BBR has been demonstrated to be less than 1% in rats ^[46]. The poor absorption is attributed to factors such as low permeability, hepatobiliary re-excretion, P-glycoprotein-mediated efflux, and self-aggregation. Furthermore, the first-pass metabolism in the liver and intestine also contributes to its low oral bioavailability ^[47]. Enhancing BBR absorption

would represent a significant advancement for the pharmaceutical development of BBR.

Based on the above-mentioned, this summary will summarize current researches on the anti-obesity efficacy of BBR and its metabolites, focus on advancements in clinical trial results, molecular mechanisms and absorption and bioavailability methods.

2. Clinical trial results about anti-obesity of BBR

Numerous recent preclinical and clinical research have increasingly focused on exploring deeper insights into the anti-obesity effects of BBR.

2.1 Effectiveness of BBR against obesity

2.1.1 Preclinical research (Table 1)

Xu et al. reported that treatment with BBR (150 mg/kg/day) for 6 weeks significantly reversed the body weight increase in HFD-fed rats, as compared with untreated HFD-fed rats, without interfering with food intake^[48]. Comparing with control group, Park et al. verified that the HFD-induced obesity mice received daily intraperitoneal injections of BBR (10 mg/kg) for 3 weeks significantly reduced food intake, body weight, fat contents, serum leptin, and glucose level^[49]. In diet-induced obesity in rats, Wang et al. reported the novel discovery that the mesenteric small arterioles are over dilated, NO is overproduced and NA production is decreased in mesenteric perivascular AT (PVAT). All these changes were reversed by BBR (200 mg/kg) through ameliorates vascular dysfunction by regulating the overproduction of NO in PVAT^[50]. Yang et al. found that orally administration of BBR (200 mg/kg) decreased serum and liver lipid levels in HFD-induced hyperlipidemic mice. Further analysis revealed that the BBR-enriched gut commensal *Blautia producta* ameliorates HFD-induced hyperlipidemia, stimulates liver LDLR expression and promoted LDL uptake by HepG2 cells^[51]. Sun et al. had a study observed that treatment with the oral administration of BBR (100 mg/kg/d, 200 mg/kg/d) alleviated HFD-induced obesity in mice^[52]. Wang et al. showed that BBR obviously reduced body weight in diet-induced obese mice, at both low dose (150 mg/ (kg·d) by gavage) and high dose

(300 mg/ (kg·d)) for 4 weeks, without apparent appetite suppression^[53]. Likewise, BBR (100 mg/kg, po) significantly ameliorated insulin resistance, reduced body weight and percent body fat and improved serum biochemical parameters and obesity effectively in HFD-mice^[54]. Gupta et al. also verified that BBR at the doses 100, 200, and 500 mg/kg (p.o.) ameliorated the total fat mass in animal models of dexamethasone (Dex) - induced to varying degrees^[47].

Table 1 Preclinical researches

Author	Processing Scheme	Result
Xu et al.	Treatment with an oral supplement of BBR for 6 weeks (150 mg/kg/day)	Treatment with BBR for 6 weeks significantly reversed the body weight increase of HFD-fed rats compared with untreated HFD-fed rats (658.58 ± 54.04 vs. 715.59 ± 46.70 g; P<0.05).
Park et al.	The mice received daily intraperitoneal injections of BBR (10 mg/kg) for 3 weeks	After BBR treatment, body weight was significantly decreased (on 66th,69th, 72th, and 75th day: P< 0.05), the relative epididymal (P < 0.05) and peritoneal fat mass (P<0.01) significantly reduced compared to HFD-fed mice. The level of leptin decreased in treated with BBR (30.8 ± 13 ng/ml) compared to HFD-fed mice (39.8 ± 4.5 ng/ml).
Wang et al.	Obese rats were treated with BBR (200 mg/kg) by gavage for 2 weeks	The administration of BBR significantly inhibited weight gain (P< 0.01), significantly improved blood sugar(P< 0.05) and blood lipid abnormalities (P< 0.01), and simultaneously corrected inflammation (IL-6, IL-1β and TNF-α, P < 0.01).
Yang et al.	Administration of BBR via oral gavage (200 mg/kg) for 56	Treatment with BBR significantly decreased body weight gain (P < 0.001) and serum lipids (P < 0.05) such as total

	days	cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), and the HFD-induced liver steatosis ($P < 0.05$).
Sun et al.	Oral administration of BBR(100mg/kg/d, 200mg/kg/d, 5times/week)	The oral administration of BBR alleviated HFD-induced obesity by a dose-dependent manner in mice that U73122 partially inhibited. BBR upregulated the release of GLP-1, promoted the proliferation of tuft cells and secretion of IL-25 in obesity via the TAS2R signaling pathway.
Wang et al.	Treatment with low dose (150 mg/ (kg·d)) and high dose (300 mg/ (kg·d)) for 4 weeks of continuous gavage	Both low and high doses of BBR effectively reduced the body weight ($P < 0.001$), reversed insulin resistance and abnormalities in glucose tolerance, reduce serum TG ($P < 0.001$), TC ($P < 0.001$), and LDL-C ($P < 0.01$) levels and elevate serum HDL-C ($P < 0.001$) level of DIO mice.
Du et al.	Treatment with BBR (100 mg/kg, po)	The oral administration of BBR significantly reduced the AUCs of the OGTT ($p < 0.01$) and the ITT ($p < 0.05$), the serum biochemical parameters, including FBG, TC, TG and LDL-C ($p < 0.01$), and volume of lipid droplets ($p < 0.05$).
Gupta et al.	Treatment with BBR at the doses of 100, 200, and 500 mg/kg (p.o.) in mice were treated with Dex (2	BBR improved glucose homeostasis in diabetic mice by enhancing glucose clearance, increasing glycolysis, elevating glucose uptake, and decreasing gluconeogenesis. Further, Dex treatment increased the total fat

	mg/kg, i.m.) for 30 days	mass in mice, which was ameliorated by BBR treatment ($p < 0.01$).
--	--------------------------	--

2.1.2 Clinical research (Table 2)

Hu et al. investigated that BBR supplementation (1.5 g/d) for 12 weeks significantly reduced blood lipid levels in obese subjects, including a 23% reduction in TG and a 12.2% reduction in TC levels⁵⁵. Bandala et al. testified that orally administration of BBR (500 mg/tablet, three times a day before each meal lasted 3 months) significantly decreased ($p < 0.05$) body weight, BMI, body fat percentage and visceral fat percentage in obese patients⁵⁶.

Table 2 Clinical researches

Author	Processing Scheme	Result
Hu et al.	Obese human subjects (Caucasian) were given 500 mg BBR orally three times a day for 12 weeks	BBR treatment produced a mild weight loss (average 5lb/subject) in obese human subjects, significantly reduced blood lipid levels (23% decrease of TG and 12.2% decrease of TC levels) in human subjects, and reduced in the rat experiment (34.7% decrease of TG and 9% decrease of TC level).
Bandala et al.	Obese patients were given orally administration of BBR (500 mg/tablet, three times a day before each meal) lasted 3 months	BBR significantly decreased ($p < 0.05$) body weight, BMI, body fat percentage, visceral fat percentage, and diastolic blood pressure.

In summary, all the above preclinical and clinical data demonstrated the anti-obesity effect of BBR, and indicated BBR's potential in the treatment of obesity. Besides, Gasmi et al. analyzed the representative studies for the years 1982-2022. Literature

analysis shows that the evidence of BBR appears to be sufficient for hands-on use for obesity^[57].

2.2 Safety of BBR against obesity

Many previous studies have demonstrated that BBR is effective and safe alternatives to synthetic drugs as a natural product. A randomized double-blind placebo-controlled clinical trial, which aimed to evaluate the potential benefit of oral supplementation of BBR PhytosomeTM (2 tablets/day, 550 mg/tablet) on the metabolic profile of subjects with impaired fasting blood glucose (IFG), indicate that the use of berberine had no adverse events^[58]. However, some studies have reported adverse reactions mainly including gastrointestinal symptoms of BBR. In Bandala's study, the main reported adverse effects in patients who were treated with BBR were nausea (20%), constipation (16%) and hemorrhoidal bleeding (28%), but these symptoms decreased within the first month of treatment. Clinical studies have shown that long-term application of BBR will bring side effects of constipation.

In response to the above, Quercetin (QR) was found to be the effective ingredient of *Amomum Villosum Lour* (AVL) in terms of relieving constipation in Cui's study, the use of QR in combination with BBR has an adverse effect-reducing efficacy^[59]. To sum up, BBR is a safe medicinal plant ingredient. Additionally, the clinical effects of BBR need to be confirmed in high-quality RCTs.

3.The potential mechanisms of BBR against obesity

3.1 The activity of BBR in suppressing adipocyte differentiation

Preadipocytes undergo a process of adipogenesis, transforming into differentiated adipocytes. This process is characterized by increased expression of adipogenic transcription factors and adipocyte-specific genes^[38]. Inhibiting these transcription factors and adipocyte-specific genes may be a key mechanism in the suppression of adipogenesis.

3.1.1 Down-regulation of C/EBP- α and PPAR- γ activities and up-regulation of PPAR- δ on 3T3-L1 adipocytes by BBR

Adipogenic differentiation is a continuous transcriptional process: CCAAT/enhancer-binding protein- β (C/EBP- β) and CCAAT/enhancer-binding protein- δ (C/EBP- δ) are transiently induced by hormonal signals, and subsequently induce directly the expression of peroxisome proliferator-activated receptor γ (PPAR- γ) and CCAAT/enhancer-binding protein- α (C/EBP- α). This activation leads to the expression of numerous downstream target genes that define adipocyte identity. During adipocyte maturation and differentiation, C/EBP- α and PPAR- γ are key adipogenic transcription factors. They promote adipogenesis by co-activating the expression of adipose-specific genes, such as AP2, and maintaining their expression at elevated levels^[60].

In other studies, the expression of C/EBP- α was detected during the early stages of 3T3-L1 adipocyte differentiation and was associated with the maintenance of PPAR- γ expression^[61]. The 3T3-L1 cell line is widely used as an adipocyte differentiation model to investigate the molecular mechanisms of adipogenesis^[38]. In fact, C/EBP- α was present in both white and brown adipocytes, where its overexpression could induce adipocyte differentiation, and its levels are further elevated in the latter stages of differentiation^[62]. The expression of C/EBP- α in fibroblasts induced adipogenesis, but only in the presence of PPAR- γ ^[63]. As a member of the nuclear receptor superfamily of ligand-activated transcription factors, PPAR- γ is crucial for adipocyte differentiation and fat formation^{[64][65]}. It is selectively expressed in adipocytes, where it regulates their metabolism and fatty acid processing^[66]. PPAR- γ increases the expression of C/EBP- δ and C/EBP- β during the early stages of differentiation and continues to elevate C/EBP- α levels to promote further differentiation^[67]. As a transcriptional factor, PPAR- δ negatively regulated C/EBP- α and PPAR- γ promoters and positively regulated the heme oxygenase-1 (Ho-1) promoter^[68].

Choi et al. demonstrated that, compared to other natural alkaloids, BBR exhibited strong inhibitory activity on adipogenesis in 3T3-L1 cells by down-regulating PPAR- γ and C/EBP- α expression in a concentration-dependent manner^[38]. Meanwhile, Shou et al. found that BBR dose-dependently increased PPAR- δ levels, and silencing

PPAR- δ abolished BBR's effect on lipid accumulation^[68]. After activating by BBR, the transcriptional functions of PPAR δ were invoked. By activating PPAR- δ expression, BBR mediated the expression of downstream genes that were functionally involved in lipid accumulation^[68].

3.1.2 Down-regulation of CREB and C/EBP- β transcriptional activity and Gal-3 activity by BBR

It has been demonstrated that the activation of cAMP-response element-binding protein (CREB) is crucial for initiating adipocyte differentiation process^[69]. Activated CREB increases the expression of C/EBP- β in the early stages of adipogenic differentiation, triggering a cascade of transcriptional events that promote the activation of C/EBP- α and PPAR- γ 2 genes, two crucial transcription factors involved in adipocyte differentiation^[69]. In addition, 3-isobutyl-1-methylxanthine (IBMX) and cAMP analogues also can promote adipocyte differentiation^[70].

Galectin-3 (Gal-3) is a member of the galectin family that binds carbohydrates or glycoproteins^[71]. Gal-3 is expressed not only by macrophages but also by adipocytes, being high in the preadipocyte fraction and almost nil in differentiated adipocytes^[72]. The mRNA and protein expression levels of Gal-3 increased in a time-dependent manner during the differentiation, proliferation and maturation of adipocytes, and Gal-3 is positively associated with obesity^[73]. Moreover, it was found that recombinant human Gal-3 stimulates preadipocyte proliferation as well as DNA synthesis through lectin-carbohydrate interaction^[72]. Gal-3 deletion results in impaired terminal adipogenic differentiation, in the absence of obvious signs of adipocyte degeneration/death and changes in both the amount and distribution of body fat^[74].

Florido et al. found that higher BMI is independently linked to elevated Gal-3^[75]. Many previous studies have shown that obesity significantly increases reactive oxygen species (ROS) levels in the vasculature, with NADPH Oxidase I (NOX1) being the most predominant source of vascular superoxide^{[76][77][78][79]}. Padgett et al. indicated that Gal-3 is most highly expressed in the microvascular endothelium in

obesity, and then confirm that Gal-3 is a novel mediator of NOX1-derived oxidative stress in the microvascular endothelium, Gal-3 oligomerization is required for NOX1 promoter activity ^[80]. Meanwhile, obesity-associated intermuscular adipose tissue (IMAT) is suggested to originate from PDGFR α ⁺ mesenchymal progenitors ^[81]. Takada et al. suggest that obesity induces excess secretion of Gal-3 from immune cells upon muscle injury/regeneration, thereby activates the PPAR- γ signaling pathway, and then induces nuclear translocation and activation in PDGFR α ⁺ cells, leading to a deviated differentiation process directed to ectopic intermuscular adipogenesis ^[82] ^[83].

Zhang et al. found that BBR primarily attenuated the IBMX and forskolin-induced phosphorylation of CREB, subsequently inhibiting the expression of C/EBP- β expression and the binding to cAMP responsive element (CRE), furthermore decreasing the expression of C/EBP- α and PPAR- γ 2 during the early stage of 3T3-L1 preadipocyte differentiation. Additionally, the inhibition of the cAMP/PKA-mediated CREB signaling pathway is a key mechanism contributing to the anti-obesity effects of BBR ^[84].

Moreover, IMAT formation during muscle regeneration was significantly suppressed in Gal-3 knockout mice by reducing the expression of key factors involved in adipogenesis, such as PPAR- γ and C/EBP- α ^[83]. Wang et al. demonstrated that BBR inhibits the differentiation and proliferation of adipocytes and reduces adiposity by decreasing Gal-3 promoter activity as well as destabilizing Gal-3 mRNA. Furthermore, BBR up-regulated microRNA (miRNA) let-7d expression, which post-transcriptionally suppresses Gal-3 ^[85]. In addition, overexpression of Gal-3 induced a further up-regulation of PPAR- γ , Gal-3 is possibly a regulator of PPAR- γ and is upstream of PPAR- γ ^[85].

3.1.3 Influence the gene expression of adipokines related with metabolic regulation by BBR

Utami et al. showed that BBR inhibits complex I of the respiratory chain, contributing to its antioxidant capability by activating the translocation of nuclear factor erythroid

2-related factor 2 (Nrf2), which increases the gene expression of superoxide dismutase (SOD), glutathione peroxidase (GPX), and reduced glutathione (GSH)^[86]. And then, BBR also have been shown to improve insulin sensitivity and stimulate glucose uptake through the activation of AMP-activated protein kinase (AMPK)^[87] and the Toll-like receptor 4 (TLR4) signaling pathway^{[4][88]}. All of these mechanisms suggest that BBR could influence the gene and protein expression of adipokines which are closely related to metabolic regulation. Meanwhile, Ye et al. considered that BBR can become a promising agent for treating metabolic syndrome and cardiovascular risk associated with obesity^[89].

3.2 The activity of BBR in browning of white adipose tissue activation and metabolism regulation

Adipose tissue (AT) is primarily composed of white adipose tissue (WAT) and brown adipose tissue (BAT) with distinct physiological functions. In addition to WAT and BAT, beige adipose tissue, serves as a transitional form between WAT and BAT. WAT stores energy from glucose and fatty acids (FA) in the form of triglycerides within large unilocular lipid droplets in adipocytes and releases energy as free fatty acids (FFA)^[90]. In contrast, BAT dissipates energy through non-shivering thermogenesis^[91]. Beige adipocytes resemble BAT in appearance but most typically emerge from a Myf5-negative cell lineage, which is similar to that of WAT^[92]. In fact, it is reported that beige adipocytes develop within subcutaneous WAT from a distinct subset of preadipocytes^[93] or through the trans-differentiation of existing WAT^{[94][95]}, the latter is known as browning of WAT. BAT is predominantly located in the neck and subscapular regions, beige adipose tissue often found within AT, whereas WAT is distributed across various body parts^[92].

The thermogenic capacity of BAT arises from its high mitochondrial content and elevated levels of uncoupling protein 1 (UCP1), which uncouples oxidative phosphorylation to generate heat instead of ATP^[96]. The identification and analysis of UCP1 stimuli can greatly facilitate our understanding of AT thermogenesis, including the browning of WAT. Gong et al. summarize the stimuli that have activated UCP1 in

recent decades, including physical and environmental factors (cold stimulation and exercise), factors related to traditional Chinese medicine (acupuncture, Chinese herbal formulas, Chinese medicinal herbs and their bioactive compounds), pharmacological agents, functional food and food ingredients, gut microbiota and pharmaceutical agents^[97].

Browning of WAT refers to the transformation of WAT into beige adipocytes, which occurs under the influence of stimuli such as exercise, cold exposure and adrenergic receptor activation. The browning process is associated with the activation of various transcriptional factors including PRDM16, PPAR- γ , PGC-1 α , COX2, PG, FGF21, BMP7, MANF, activin E, C/EBP- β , myokines, zinc finger protein 516, ATGL, adiponectin, and irisin. More recently, there have been a number of findings about the browning of WAT. Kim et al. suggested that beta-hydroxybutyrate (β -HB) reduced intracellular lipid accumulation by activating mitochondrial biogenesis, enhancing lipolysis and stimulating the expression of thermogenic and fat browning genes^[98]. Wang et al. unravel that EDN3/EDNRB signaling induces the thermogenic differentiation of white adipose progenitor cells via activating intracellular cAMP and EPAC1-ERK-mediated pathways^[99]. In human visceral adipocytes, Neira et al. investigated that Fibronectin type III domain-containing protein 5 (FNDC5) /irisin triggered mitochondrial biogenesis (TFAM) and fusion (MFN1, MFN2, and OPA1) while inhibiting peripheral fission (DNM1L and FIS1) and mitophagy (PINK1 and PRKN), and then stimulating the browning of WAT process in response to cold and obesity^[100]. Wang et al. found that the β 3-adrenergic receptors (β 3ARs)-activated mTOR-lipin1 axis mediates browning of WAT^[101]. Zhou et al. demonstrated that the nuclear receptor subfamily 2 group F member 6 (NR2F6) played a pivotal role in brown adipogenesis and energy homeostasis, NR2F6 transcriptionally regulated PPAR- γ expression to promote adipogenic process in BAT^[102].

The expression of BAT marker genes (PGC-1 α and UCP1), transcription factors (PPAR- α , nuclear respiratory factor 1 and mTFA) and mitochondrial biogenesis (ATPsyn, COXIV and Cyto C) were concurrently activated in fractionated and

differentiated primary IWAT which were treated with BBR ^[103]. Meanwhile, BBR chloride, a dual topoisomerase I and II inhibitor, Ferdous et al. found that it significantly up-regulated UCP1 gene expression and down-regulated ATP production in BAT which reduced adipocyte content by initiating thermogenesis ^[104]. The activation of AMPK and PGC-1 α also plays a significant role in the thermogenic induction by BBR ^[103]. Yao et al. indicated that BBR attenuates the abnormal ectopic lipid deposition in skeletal muscle by promoting the mitochondrial biogenesis and improving fatty acid oxidation in an AMPK/PGC-1 α dependent manner^[105]. Ling et al. demonstrated that BBR epigenetically acts through the AMPK- α -ketoglutarate (α -KG)-PRDM16 axis to promote brown adipogenesis and BAT thermogenesis. BBR increases the transcription of PRDM16 by inhibiting DNA demethylation of the PRDM16 promoter, likely driven by AMPK activation and the production of the tricarboxylic acid cycle intermediate α -KG^[106]. Sun et al. provided both in vivo and in vitro evidence that BBR promotes the browning of WAT to enhance energy expenditure and weight loss by stimulating NAD⁺-dependent deacetylase SIRT1 activity and inducing autophagy in an autophagy protein 5-dependent manner, as well as inducing the production and secretion of FGF21 ^[107]. Growth differentiation factor 15 (GDF15), a distant member of the transforming growth factor- β superfamily, forms a ternary complex with glial cell-derived neurotrophic factor family receptor alpha-like (GFRAL) and the receptor tyrosine kinase in the hypothalamus to reduce energy intake by suppressing appetite. Peripheral GDF15 can also promote thermogenesis and lipolysis while reducing adipose tissue mass ^[108]. Li et al. found that BBR increases serum levels of GDF15 and have shown that BBR lowers body weight by up-regulating GDF15 secretion and expression via the activation of the integrated stress response (ISR) in BAT ^[108].

Above mentioned evidences consistently identified that BBR and its derivatives are crucial factors in promoting adaptive thermogenesis by activating BAT activity and the browning of WAT process.

3.3 The hypolipidemic activity of BBR

Obesity alters lipids metabolism due to high triglycerides, high LDL-C, and high total cholesterol, leading to endothelial dysfunction and atherosclerosis, contribute to atherosclerotic diseases^{[109] [110] [111]}. Foam cell formation is the initial pathological process of atherosclerotic diseases. Guan et al. found that BBR activates the AMPK-SIRT1-PPAR- γ pathway, inhibiting the expression of lectin-like oxidized LDL receptor 1 (LOX-1), which impedes foam cell formation^[112]. Foam cell accumulation leads to fibrous plaques that evolve into atherosclerotic plaques^[113]. Through activating nuclear factor erythroid 2 - related factor 2 (NRF2)/recombinant solute carrier family 7 member 11 (SLC7A11)/glutathione peroxidase 4 (GPX4) pathway and inhibiting ferroptosis in endothelial cells acting as an ACSL4 inhibitor, BBR can resist oxidative stress, inhibit ferroptosis, reduce plaque area and stabilize plaque^{[114] [115]}.

Meanwhile, obese patients mainly show expansion of adipose tissue and hypertrophy of adipocytes^[116]. Adipocyte hypertrophy leads to the synthesis of adipokines mainly including visfatin (Vis), resistin (Res), apelin (Ap) and omentin (Ome) that have different physiological functions^[117]. Recent Bandala's research has shown that BBR lowers the harmful adipokines expression of Vis and Ap, and enhanced the protective adipokines of Ome, which can be explained by BBR enhances lipid metabolism and fatty acid oxidation, and reduces adipogenesis and IR in adipocytes, thereby alleviating obesity and inflammation^[56].

Two clinical trials in patients with dyslipidemia have demonstrated that BBR can reduce triglycerides by 35% and 22%, serum cholesterol by 29% and 16%, and LDL-C by 25% and 20%, respectively^{[118] [119]}. Du et al. certified that BBR reduced triglyceride level and lipid droplet volume in hypertrophic adipocytes, further demonstrated that BBR inhibited miR-27a levels which induced IR status in serum from obese mice^[54].

Studies have also linked the hypolipidemic activity of BBR to low density lipoprotein receptor (LDLR) mediated cholesterol metabolism. BBR can up-regulate LDLR expression in liver cells through AMPK-dependent Raf-1 activation^[120]. The BBR can also induce the stabilization of LDLR mRNA by activating the extracellular

signal-regulated kinase (ERK) signaling pathway and down-regulating the mRNA decay-promoting factor heterogeneous nuclear ribonucleoprotein D (hnRNP D)^[121]^[122]. Lee et al. showed that the effect of BBR on LDLR was blocked by a c-Jun N-terminal kinase (JNK) inhibitor, suggesting that JNK activation was involved^[123]. Similarly, BBR (at 50 and 100 mg/kg) in a tilapia model reduced plasma lipid levels but increased the expression of the PPAR- α and carnitine palmitoyltransferase 1 (CPT-1) genes in the liver, leading to reduced lipid accumulation^[124].

Additionally, BBR treatment can increase the conversion of cholesterol to bile acid, thereby reducing blood cholesterol levels^[125]. CYP7A1 and SREBP are considered the classical rate-limiting enzyme and transcriptional factor for the conversion of cholesterol to bile acid^[126], and the hypolipidemic effect of BBR may be related to its up-regulation of SREBP2 and CYP7A1 expression and the promotion of bile acid metabolism^[127].

Previous studies have shown that lacteals are responsible for draining chylomicrons, which are triglyceride-rich and processed by enterocytes, into the lymphatic system via the interstitial space among the lymphatic endothelial cells (LECs) on the lacteals^[128]. Zhang et al. demonstrated that diet-induced obesity can be inhibited by converting the discontinuous and open "button-like" LEC junctions into continuous and closed "zipper-like" junctions, thereby reducing the entry of chylomicrons into the lacteals^[129]. Based on these findings, Wang et al. provided novel evidence for one of the hypolipidemic mechanism of BBR. They determined that BBR inhibits lipid absorption by promoting lacteal junction zipping and verified that BBR promoted the formation of mature LEC junctions via the suppression of the Ras homolog gene family member A (RhoA)/Rho-associated kinase 1 (ROCK1) signaling pathway^[53].

3.4 Regulation of the gastrointestinal microbiota (GM) by BBR

Previous studies had revealed that BBR have antibacterial activity through the inhibition of protein and DNA synthesis pivotal to bacterial growth and proliferation. Consequently, it effectively halts the division and development of various common

bacterial strains ^[130] ^[131] ^[132]. Ye et al. confirmed that BBR exhibits antimicrobial effects on hemolytic *Streptococcus*, *Staphylococcus aureus*, *Neisseria gonorrhoeae*, and Freund's *Shigella*, and can improve leukocyte phagocytosis ^[133]. And then, BBR can significantly reduce the abundance of Proteobacteria such as *Desulfovibrio* and *Enterobacter cloacae*, inhibiting lipopolysaccharide (LPS) production and effectively attenuating serum LBP, a biomarker of circulating LPS, thereby improving metabolic endotoxemia ^[134]. Disturbances in the Firmicutes/Bacteroidetes ratio in the gut microbiota have been associated with various diseases, including obesity^[135]. Xie et al. showed that administering BBR at a dose of 200 mg/kg for six weeks significantly reduced the relative abundances of the phyla Bacteroidetes and Firmicutes in the gut of HFD-fed mice, and systematically increased the expression of fasting-induced adipose factor genes in visceral AT (VAT) ^[136]. BBR has also been shown to enrich the population of butyrate-producing bacteria in the gut microbiota, promoting butyrate synthesis via the acetyl-CoA-butyryl-CoA-butyrate pathway. Subsequently, butyrate enters the bloodstream, reducing lipid and glucose levels ^[134]. Wu et al. demonstrated that BBR and its derivatives exert lipid-lowering effects by mediating gut microbiota, identifying *Blautia* as a critical commensal genus for its anti-hypercholesterolemic action. They also noted that baseline levels of *Alistipes* and *Blautia* could precisely predict the efficacy of BBR against hypercholesterolemia ^[137]. Sun et al. reported that BBR increased the Bacteroidetes /Firmicutes ratio and the proportion of SCFA-producing bacteria by regulating the GM-gut-brain axis, which in turn promoted the expression of GLP-1 in intestinal L cells ^[138]. Yang et al. investigated the effects of BBR metabolites on GLP-1 secretion, demonstrating that BBR significantly increased the production and glucose-stimulated secretion of GLP-1 in GLUTag cells by alleviating cell death, oxidative stress, mitochondrial dysfunction, and reversing inflammation-induced inhibition of the Akt signaling pathway ^[139]. Sun et al. also revealed that BBR can bind to bitter-taste receptors (TAS2Rs) to promote GLP-1 secretion and enhance downstream G α -gustducin/G β 1 γ 13 signaling in tuft cells in the gut. This activity also increases IL-25 production and

repairs the compromised gut barrier integrity induced by obesity^[52].

Similarly, Wang et al. found that BBR strengthens the intestinal barrier by ameliorating endoplasmic reticulum (ER) stress and reducing goblet cell apoptosis through decreased mucin-2 expression^[140]. *Akkermansia muciniphila* (*A. muciniphila*) has been identified as a mucin-degrading bacterium in the mucus layer^[141]. Previous studies have shown a reduced abundance of *A. muciniphila* in obese humans^[142]. Wang et al. demonstrated that BBR can significantly increase the abundance of bacteria of the phylum Verrucomicrobia, particularly *A. muciniphila*, which leads to the regulation of tight junction proteins and protection of intestinal barrier integrity^[140]. Moreover, Chen et al. showed that administration of BBR could alleviate intestinal barrier dysfunction of glucolipid metabolism disorders (GLMDs) by increasing the number of colonic glands and goblet cell mucus secretion, promoting the proliferation of beneficial microbiota, and altering the levels of tryptophan metabolites, intestinal tight junction proteins and intestinal immune factors^[143].

Additionally, BBR acts as an α -glucosidase inhibitor, breaking down carbohydrates into monosaccharides and diminishing the absorption of dietary carbohydrates. BBR's α -glucosidase inhibitory activity also confers significant antimicrobial effects by inhibiting the assembly function of FtsZ and halting bacterial cell division in the gastrointestinal tract^[144].

3.5 BBR in adipose tissue macrophages (ATMs) recruitment and polarization

Macrophages are typically classified into M0, M1 and M2 types: M0 macrophages are quiescent cells capable of phagocytizing cell debris, M1 macrophages exhibit phagocytic and pro-inflammatory properties and M2 macrophages are associated with attenuated inflammation and tissue deposition^[145]. Numerically the population of ATMs expands from 10% of all cells in lean AT to more than 50% in severe obesity in mice^[146]^[147]. Macrophage numbers increase in AT in obese humans, with the percentage of ATMs rising from 5% - 10% in the lean healthy status to 40% - 50% of

the stromal cells in the obese setting^[148]. Russo et al. give a conclusion that ATMs are key mediators of meta-inflammation, IR and impairment of adipocyte function with progressive obesity, which consistent with above-mentioned clinical data^[149]. Based on this, many groups have studied the relationship and mechanism between BBR and ATM.

Noh et al. reported that BBR significantly reduced body weight, adipocyte size, fat deposition in the liver, and ATM infiltration in C58BL/6 mice fed with high fat diet (HFD)^[150]. In addition, an increased number of the CD206⁺ M2 ATM cells were noticed. It was proposed that BBR led to weight loss in the HFD model by modulating ATM recruitment and polarization via chemotaxis inhibition^[150]. Gong et al. had a study unveiled that BBR decreased monocyte chemoattractant protein-1 (MCP-1) expression, while diminishing macrophage infiltration and decreasing M1 proportion as determined by RT-qPCR^[151]. Additionally, Wu et al. camouflaged BBR-loaded PLGA nanoparticles (BBR NPs) with M2 macrophage cell membrane and loaded them with Man, which induce the polarization of M1 macrophages toward the M2 phenotype upon reaching the plaque, thereby mitigating local inflammation and exerting anti-inflammatory effects, increasing collagen levels in the aorta, reducing lipid deposition in plaques and improving plaque stability^[152]. Lin et al. also verified that BBR treatment in mice fed with the high-fat diet increased energy metabolism, glucose tolerance, and expression of UCP1, and reduced expression of pro-inflammatory cytokines, macrophage recruitment, and resulted in M2 macrophage polarization in WAT^[153]. These findings underscore the pivotal role of macrophages in the development of obesity, rendering their metabolic modulation a promising therapeutic target^[154].

Zhang et al. identified that BBR could reduce the acetylation of p65 at site Lys310, thereby weakening the translocation of p65 and inhibiting p300/ac-p65Lys310 signaling in macrophages and leading to the decline of NF-κB activity^[155]. NLRP3 (Nod-like receptor family pyrin domain containing 3) inflammasome has been reported to contribute to obesity-induced inflammation and insulin resistance. Zhou et al. demonstrated that BBR significantly inhibited the

NLRP3 inflammasome activation and interleukin-1 β (IL-1 β) release triggered by saturated fatty acid palmitate (PA) in macrophages. This inhibitory effect was mediated through the induction of autophagy in ATMs in an AMPK-dependent manner, highlighting the potential of BBR in modulating inflammatory responses^[156]. Zhang et al. presented a novel perspective suggesting that BBR, when combined synergistically with isoliquiritigenin (ISL), upregulates the IRS1-PI3K-Akt insulin signaling pathway, thereby enhancing glucose uptake and mitigating the interaction between macrophages and adipocytes. This combination also reduces the accumulation and infiltration of M1-ATMs^[157].

3.6 The activity of BBR in improving adipose tissue inflammation

Chronic inflammation may contribute to a variety of disorders, such as diabetes, obesity, rheumatoid arthritis, atherosclerosis and cancer^{[158] [159]}. WAT accumulation and inflammation contribute to obesity by inducing insulin resistance^[157]. In the obese state, long-term overactivation of ATMs results in chronic low-grade inflammation and a shift in the adipose immune landscape^[160]. The classically activated ATMs (M1-ATMs) secrete a variety of cytokines including IL-6 and TNF- α , and chemokines, such as macrophage inflammatory protein-1 α (MIP-1 α) and MCP-1, which result in low-grade chronic inflammation^[149].

Li et al. demonstrating that BBR mitigates adipose tissue inflammation by suppressing macrophage infiltration into eWAT in HFD-fed mice^[160]. Similarly, BBR significantly down-regulated the expression of the NLRP3 inflammasome and its associated molecules in macrophages, thereby mitigating NLRP3 inflammasome activation-induced macrophage M1 polarization and inflammation^[161]. In addition, recent research has shown that BBR increased the gene expression of the antioxidant components erythroid 2-related factor 2 (NRF-2), heme oxygenase 1 (HO-1), and glutathione-S-transferase- α (GST- α), and reduced inflammation by decreasing Toll-like receptor-2 (TLR-2), myeloid differentiation protein-88 (MYD-88), interleukin-1 β (IL-1 β), tumor necrosis factor- α (TNF- α), and interleukin-8 (IL-8) gene

expression^[124].

The deacetylase SIRT3 regulates mitochondrial biogenesis and function, and its expression level and activity are decreased in obesity^[162]. Notably, BBR suppresses TNF- α -mediated inflammation in differentiated adipocytes, at least partially by directly binding and activating the deacetylase SIRT3 and suppressing the activation of the MAPK and NF- κ B signaling pathways^[160]. Meanwhile, Meng et al. firstly identified IRGM1 as the direct anti-inflammatory target of BBR in cell culture-activity-based protein profiling (SILAC-ABPP). Further clarification that the molecular mechanism of BBR's anti-inflammatory activity was inhibiting the PI3K/AKT/mTOR pathway by targeting IRGM1^[163]. Yang's results revealed that berberrubine (BBR) and palmatine (PMT), out of BBR metabolites, alleviated cell death, oxidative stress, and mitochondrial dysfunction and effectively reverse inflammation-induced inhibition of the Akt signaling pathway in mice with obesity induced by HFD^[139].

Obesity and IR are common characteristics of polycystic ovary syndrome (PCOS)^[164]. As one of the common causes of obesity in women, PCOS also associated with AT inflammatory response and apoptosis^[165]. Shen et al. had some findings that BBR may alleviate the inflammatory response of PCOS rats by regulating the expression of inflammation-related genes, including TLR4, LYN, NF- κ B, TNF- α , IL-1 and IL-6. Additionally, BBR may improve PCOS via the PI3K/Akt/NF- κ B signaling pathway^[166].

4. Better formulation to improve the anti-obesity activity of BBR

Despite the beneficial effects and high safety profile of BBR, its poor bioavailability due to low intestinal absorption remains a significant limitation in its clinical application. BBR will need improved formulations or completed targeted delivery systems to enhance its potency before it can effectively compete with GLP-1 agonists in weight loss clinical trials. In addition, new salt or new crystal form of BBR may also improve its bioavailability.

4.1 Rational combinations of active compounds from herbs

For compounds with poor absorption and low bioavailability, such as BBR, combining active ingredients from herbs offers a potential approach to enhance therapeutic effects, allowing BBR to be effective at much lower doses.

Insulin - sensitizing phytonutrients, such as cinnamaldehyde and curcumin, are known inhibitors of protein serine/threonine phosphatases and protein tyrosine phosphatases. These inhibitors increase phosphorylation of Akt2 at T450 and Y475, priming Akt2 for subsequent activation via insulin-stimulated phosphorylation at S474^[167]. Urasaki et al. presented a rational composition of phytonutrients (F2) comprising cinnamaldehyde, curcumin, and BBR. This composition protects against obesity and pre-diabetic conditions in a diet-induced obesity murine model, providing an effective means to improve insulin sensitivity without increasing adiposity^[168]. Similarly, Yue et al. demonstrated that astragalus polysaccharides (APS) combined with BBR were more effective than APS or BBR alone in reducing obesity and modulating the gut microbiota in HFD-fed mice^[169]. Meanwhile, BBR acted synergistically with ISL to significantly ameliorate obesity and dyslipidemia in DIO mice, and can be a promising and effective strategy for improving obesity-induced adipose inflammation and insulin resistance^[157]. Additionally, dual and triple combinations of BBR, catechin, and capsaicin, have shown better potential than single active ingredients^[170]. In obese and diabetic patients, BBR combined with silymarin significantly reduced fasting blood glucose and insulin, the IR index, HDL and LDL, triglycerides, uric acid, BMI, and the WHR compared with the use of BBR alone^[171].

In Lin's study, a water-soluble tetraanionic macrocycle has been revealed to be highly biocompatible and efficiently included encapsulate discrete electron-deficient aromatic compounds (including BBR and palmatine) through parallel-arrangement encapsulation, and this macrocycle is able to inhibit the bitter taste of the two drugs^[172].

4.2 A co-crystalized BBR-ibuprofen

The drug co-crystal refers to a crystal composed of the active pharmaceutical ingredient (API) and a co-crystal former (CCF) bonded by non-covalent interactions

^[173]. Drug co-crystals can enhance the physicochemical and biopharmaceutical properties of APIs ^[174].

Wang et al. prepared a 1:1 co-crystal of BBR and ibuprofen (termed BJ) using drug salt metathesis and co-crystal technology. Compared to the common BBR salt (BBR chloride dihydrate, BCl·2H₂O), BJ demonstrated a threefold increase in bioavailability in vivo and was more effective in treating obesity and related metabolic disorders in the db/db mice model ^[175]. It was reported that BJ inhibited the expression of IKK ϵ and TBK1 in the epididymal WAT (eWAT) of db/db mice, but had no effect on these proteins in BAT. TBK1 directly inhibits the phosphorylation of AMPK- α at the Thr172 site (p-AMPK- α) in adipocytes, regulating UCP-1 and mitochondrial biogenesis ^[176]. IKK ϵ reduces cAMP levels in adipocytes and inhibits cAMP-mediated β -adrenergic signal transduction, leading to catecholamine resistance and reduced lipolysis and thermogenesis ^[177]. Thus, studies with BJ revealed that BBR could promote mitochondrial biogenesis and increases adipocyte sensitivity to catecholamines by inhibiting the activity of non-canonical I κ B kinases TBK1 and IKK ϵ , and induces AMPK phosphorylation ^[175].

4.3 Delivery systems

Numerous researches consistently suggest that biomimetic nanomaterials by fusing natural cell membranes onto nanoparticles (NPs) ^[178] that coat cell membranes have been extensively researched in recent years due to it enables nanoparticles to evade the immune system ^[179] ^[180], extend their circulation in the bloodstream ^[181] ^[182] and facilitate the targeted uptake by specific homologous cells ^[183]. Based on this, Wu et al. developed BBR NPs@Mannose (Man)/M2 nanoparticles to enhance the bioavailability of BBR ^[152]. Meanwhile, Xu et al. develop a novel nanoemulsion (NE) that increase the oral bioavailability of BBR in rats by 212.02%, BBR-loaded NE protect BBR against the intestinal metabolism mediated by CYP2D6 and CYP3A4 ^[184].


Additionally, Mirhadi et al. describes different types of nanocarriers (polymeric based, magnetic mesoporous silica based, lipid based, dendrimer based, graphene based,

silver and gold nanoparticles) have been used for encapsulation of BBR to improve its bioavailability ^[185]. Erythrocytes have been extensively studied for their biocompatibility, safety, the preferential uptake and high drug loading efficiency in vascular carriers ^[186] ^[187]. An erythrocyte-based drug delivery system for BBR has been developed to target macrophages and increase biocompatibility, enhance therapeutic efficacy in combating inflammation and hypolipidemic effect, achieve long circulation and sustain release of BBR ^[188].

4.4 Derivatives of BBR

Tetrahydroberberrubine (THBru, figure 2), a derivative of BBR, was found to markedly ameliorate obesity, dyslipidemia, and decrease Lee's index, fat mass in eWAT and BAT in HFD-induced obese mouse model through the activation of PGC1 α -mediated thermogenesis. Notably, THBru was demonstrated to exhibit superior efficacy compared to BBR at the same dose ^[189].


Figure 2 Chemical Construction of THBru



Oxyberberine (OBB, figure 3), a gut microbiota-mediated oxidative metabolite of BBR. Li et al. firstly identified that OBB remarkably and dose-dependently attenuated the clinical manifestations in HFD-induced obese NAFLD rats, which was superior to BBR of the same dose (100 mg/kg). Meanwhile, compared with BBR, they further proof that OBB treatment remarkably up-regulates UCP-1 protein expression to increase expenditure of energy by exhibiting superior hyperphosphorylation of


AMPK in vivo, alleviated inflammation and IR to maintain lipid homeostasis by significantly inhibiting aberrant phosphorylation of IRS-1, down-regulating the mRNA expression of MCP-1, Cd68, Nos2, Cd11c, while up-regulating the downstream protein expression and phosphorylation (PI3K, p-Akt/Akt and p-GSK-3 β /GSK-3 β)^[190].

Figure 3 Chemical Construction of OBB




9-N-alkyltetrahydroberberine (figure 4) is also a derivatives of BBR. Just administration of this substance at a dose of 15 mg/kg for four weeks significantly improved the insulin sensitivity of obesity mice, and the mass of AT was demonstrated lower than in untreated obesity mice^[191].

Figure 4 Chemical Construction of 9-N-alkyltetrahydroberberine




Similarly, a new derivative of BBR, 9-(hexylamino)-2,3-methylenedioxy-10-methoxyprotoberberine chloride (SHE-196, figure 5) decreased total body weight and interscapular fat mass, and increased interscapular brown fat activity in obese T2DM mice ^[192].

Figure 5 Chemical Construction of SHE-196




In addition, the reduced derivative of BBR, dihydroberberine (dhBBR, figure 6), has been suggested as a natural alternative of BBR to improve bioavailability ^[193]. A randomized, double-blind, placebo-controlled investigation determined that four doses of a 100 mg dose of dihydroberberine and 200 mg dose of dihydroberberine produce significantly greater concentrations of plasma BBR across of two-hour measurement window when compared to a 500 mg dose of BBR or a placebo (BBR level: PLA: 0.22 ± 0.18 ng/mL, B500: 0.4 ± 0.17 ng/mL, D100: 3.76 ± 1.4 ng/mL, D200 : 12.0 ± 10.1 ng/mL; BBR AUC: PLA: 20.2 ± 16.2 ng/mL \times 120 min, B500: 42.3 ± 17.6 ng/mL \times 120 min, D100: 284.4 ± 115.9 ng/mL \times 120 min, D200: 929 ± 694 ng/mL) ^[194].

Figure 6 Chemical Construction of dhBBR




The bioavailability, however, could be significantly enhanced through introduction of lipophilic substituents. Among all lipophilicity-enhancing strategies, C9-O-Me substitution is the most intensively studied one, which is primarily due to its synthetic convenience. Teng et al. herein reported the first synthetic study on 9-O-arylated BBR (figure 7) via copper-catalyzed CAr-O coupling reactions, and provided a new perspective on the preparation of more diverse BBR derivatives in the future^[195].

Figure 7 Chemical Construction of 9-O-R BBR



Cheng et al. synthesized the 8,8-dimethyldihydroberberine (Di-Me, figure 8) with improved stability, and bioavailability over dhBBR. Administered to db/db mice with a dosage of 50mg/kg, Di-Me effectively reduced random fed and fasting blood glucose, improved glucose tolerance, alleviated insulin resistance and reduced plasma triglycerides, with better efficacy than dhBBR at the same dosage^[196].

Figure 8 Chemical Construction of Di-Me



Di-Me

5 Summary

BBR, a quaternary isoquinoline alkaloid with potent pharmacological properties, is currently attracting significant attention for obesity treatment. Numerous studies have confirmed BBR's potential to mitigate obesity through various mechanisms (Figure 9). One key mechanism involves down-regulating genes that promote adipocyte proliferation and differentiation. Meanwhile, BBR influence other gene expression of adipokines related with metabolic regulation. Furthermore, BBR regulates the activation of BAT and the process of browning of WAT and metabolism, contributing to obesity treatment. And then, BBR regulates the lipid and plaque metabolism. In addition, BBR can alter the composition of gastrointestinal microbiota and strengthen intestinal barrier. Eventually, BBR promotes the polarization of ATMs towards the M2 phenotype, suppresses the activation of inflammatory signaling pathway and inflammatory cytokines.


Recent breakthroughs in researches include BBR's regulation of AMPK and PGC-1 α activation, activation of the AMPK- α -KG-PRDM16 axis, stimulation of SIRT1 deacetylation activities, induction of FGF21 secretion through autophagy, and increased serum levels of GDF15. Additionally, BBR can alleviate AT growth by inducing enzymes that enhance glucose and FA uptake. Recent advancements also show that BBR promotes dyslipidemia metabolism by up-regulating LDLR

expression via JNK activation, down-regulating LOX-1 expression through the AMPK-SIRT1-PPAR- γ pathway, and up-regulating expression of SREBP2 and CYP7A1. BBR has also been shown to promote LEC mature junction formation via suppression of the RhoA/ROCK1 signaling pathway. Studies indicate that BBR may improve IR and address obesity-associated cardiovascular diseases by influencing gut microbiota composition. Notable findings include BBR's ability to increase GLP-1 expression via TAS2Rs signaling pathway.

Despite its promise, BBR's low bioavailability and poor oral absorption have limited its clinical application. Recent research on the anti-obesity effects of BBR highlights rational combinations of herbs based on functional complementarity, co-crystal BBR-ibuprofen compounds, the construction of drug delivery systems targeting WAT and the development of derivatives (Figure 9). These advancements provide a theoretical basis for the more precise clinical use of BBR in promoting weight loss.

BBR has significant potential as a new drug for treating metabolic syndrome and hereditary endocrine diseases. However, this review only covers a portion of the recently discovered mechanisms of BBR against obesity. Most experiments have been conducted in rodents, whose fat distribution and metabolism differ from those of humans. Furthermore, the specific regulatory mechanisms of fat activation are complex and require further research to elucidate their benefits for human health. Although weight loss has been observed in patients enrolled in some clinical studies involving the common BBR chloride salt, these trials are not specifically designed for obesity treatment. In the future, more high-quality clinical trials need to be conducted to investigate the dose-response effects, optimize the optimal treatment period, and uncover the molecular mechanisms of BBR. This review can provide reference for further research and rational use of BBR in the treatment of obesity.

Figure 9 Summary of BBR



6. Declarations

(1) Ethics approval and consent to participate

Not applicable.

(2) Consent for publication

The review in this paper have not been published previously in whole or part, all authors unanimously consent for publication.

(2) Availability of data and materials

Not applicable.

(3) Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

(4) Funding

This work was supported by Priority Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University (No.202201AY070001-066), Funding of the "famous doctors" project of the support

plan for the talents of Xingdian (No.RLMY20220005), The scientific and technological innovation team of Kunming Medical University (CXTD202209), Yunnan Provincial Endocrinology and Metabolism Clinical Medicine Center (YWLCYXZXXYS20221005), Clinical Collaboration Project of Traditional Chinese and Western Medicine for Major Difficult Diseases of Yunnan Province (300073).

(6) Authors' contributions

Y.K. and H.K.Y. were responsible for manuscript writing. R.N. and F.Z. were responsible for searching literature. X.Y.Z. and H.T.Z. provided manuscript writing guidance for the review. X.N. provided financial support. All authors have read and approved the final manuscript.

(7) Acknowledgements

This work was supported by Priority Union Foundation of Yunnan Provincial Science and Technology Department and Kunming Medical University (No.202201AY070001-066), Funding of the "famous doctors" project of the support plan for the talents of Xingdian (No.RLMY20220005), The scientific and technological innovation team of Kunming Medical University (CXTD202209), Yunnan Provincial Endocrinology and Metabolism Clinical Medicine Center (YWLCYXZXXYS20221005), Clinical Collaboration Project of Traditional Chinese and Western Medicine for Major Difficult Diseases of Yunnan Province (300073).

References

【1】 Sørensen TIA, Martinez AR, Jørgensen TSH. Epidemiology of Obesity. *Handb Exp Pharmacol.* 2022;274:3-27. doi: 10.1007/164_2022_581. PMID: 35419622.

【2】 Koliaki C, Dalamaga M, Liatis S. Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? *Curr Obes Rep.* 2023 Dec;12(4):514-527. doi: 10.1007/s13679-023-00527-y. Epub 2023 Oct 2. Erratum in: *Curr Obes Rep.* 2023 Dec;12(4):528. doi: 10.1007/s13679-023-00533-0. PMID: 37779155; PMCID: PMC10748771.

【3】 World Obesity Federation. *World Obesity Atlas 2024.* <https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2024>.

【4】 Ilyas Z, Perna S, Al-Thawadi S, Alalwan TA, Riva A, Petrangolini G, Gasparri C, Infantino V, Peroni G, Rondanelli M. The effect of Berberine on weight loss in order to prevent obesity: A systematic review. *Biomed Pharmacother.* 2020 Jul;127:110137. doi: 10.1016/j.biopha.2020.110137. Epub 2020 Apr 27. PMID: 32353823.

【5】 Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. *Nat Rev Drug Discov.* 2022 Mar;21(3):201-223. doi: 10.1038/s41573-021-00337-8. Epub 2021 Nov 23. PMID: 34815532; PMCID: PMC8609996.

【6】 Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. *Obes Rev.* 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290.

【7】 Popa MM, Sirbu AE, Malinici EA, Copaescu C, Fica S. Obesity-related renal dysfunction: gender-specific influence of visceral adiposity and early impact of metabolic and bariatric surgery. *Front Endocrinol (Lausanne).* 2024 Oct 14;15:1440250. doi: 10.3389/fendo.2024.1440250. PMID: 39469576; PMCID: PMC11513314.

【8】 Dugdale EM, Uvodich ME, Pagnano MW, Berry DJ, Abdel MP, Bedard NA. Early adverse outcomes remain challenging to prevent in morbidly obese patients undergoing total hip arthroplasty. *Bone Joint J.* 2024 Nov 1;106-B(11):1223-1230. doi: 10.1302/0301-620X.106B11.BJJ-2023-1187.R1. PMID: 39481442.

【9】 Chao AM, Quigley KM, Wadden TA. Dietary interventions for obesity: clinical and mechanistic findings. *J Clin Invest.* 2021 Jan 4;131(1):e140065. doi: 10.1172/JCI140065. PMID: 33393504; PMCID: PMC7773341.

【10】 Dragano NRV, Fernø J, Diéguez C, López M, Milbank E. Recent Updates on Obesity Treatments: Available Drugs and Future Directions. *Neuroscience.* 2020 Jun 15;437:215-239. doi: 10.1016/j.neuroscience.2020.04.034. Epub 2020 Apr 29. PMID: 32360593.

【11】 WolWolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. *Circ Res.* 2016 May 27;118(11):1844-55. doi: 10.1161/CIRCRESAHA.116.307591. PMID: 27230645; PMCID: PMC4888907.

【12】 Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. *BMJ.* 2014 Aug 27;349:g3961. doi: 10.1136/bmj.g3961. PMID:

25164369; PMCID: PMC4707708.

【13】 Strohacker K, Carpenter KC, McFarlin BK. Consequences of Weight Cycling: An Increase in Disease Risk? *Int J Exerc Sci.* 2009;2(3):191-201. PMID: 25429313; PMCID: PMC4241770.

【14】 Simonds SE, Pryor JT, Cowley MA. Repeated weight cycling in obese mice causes increased appetite and glucose intolerance. *Physiol Behav.* 2018 Oct 1;194:184-190. doi: 10.1016/j.physbeh.2018.05.026. Epub 2018 May 26. PMID: 29842854.

【15】 Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. *Circulation.* 2012 Mar 6;125(9):1157-70. doi: 10.1161/CIRCULATIONAHA.111.039453. PMID: 22392863; PMCID: PMC3313649.

【16】 Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. *Drug Saf.* 2006; 29(4):277-302. doi: 10.2165/00002018-200629040-00001. PMID: 16569079.

【17】 Jefferson HJ, Jayne DR. Peripheral vasculopathy and nephropathy in association with phentermine. *Nephrol Dial Transplant.* 1999 Jul;14(7):1761-3. doi: 10.1093/ndt/14.7.1761. PMID: 10435891.

【18】 Parthvi R, Mehra S. Topiramate-Associated Renal Tubular Acidosis. *Am J Ther.* 2018 Nov/Dec;25(6):e772-e773. doi: 10.1097/MJT.0000000000000781. PMID: 29782342.

【19】 Kinalp C, Kurultak I, Ceri M, Keskinel I. Serum creatinine elevation caused by bupropion. *Wien Klin Wochenschr.* 2014 Feb;126(3-4):138-9. doi: 10.1007/s00508-013-0466-4. Epub 2013 Dec 17. PMID: 24343039.

【20】 Mutoh J, Ohsawa M, Hisa H. Effect of naloxone on ischemic acute kidney injury in the mouse. *Neuropharmacology.* 2013 Aug;71:10-8. doi: 10.1016/j.neuropharm.2013.03.001. Epub 2013 Mar 19. PMID: 23523991.

【21】 Erken E, Altunoren O, Gungor O. Orlistat and acute kidney injury: a case report. *Clin Nephrol.* 2017 Mar;87 (2017)(3):157-158. doi: 10.5414/CN109029. PMID: 28177280.

【22】 Colbourne JRM, Fisher OM, Mo S, Rigas GS, Talbot ML. The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss

following bariatric surgery. *Langenbecks Arch Surg.* 2023 Mar 3;408(1):115. doi: 10.1007/s00423-023-02805-8. PMID: 36867261; PMCID: PMC9984502.

【23】 Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. *JAMA Netw Open.* 2022 Sep 1;5(9):e2231982. doi: 10.1001/jamanetworkopen.2022.31982. PMID: 36121652; PMCID: PMC9486455.

【24】 Smits MM, Van Raalte DH. Safety of Semaglutide. *Front Endocrinol (Lausanne).* 2021 Jul 7;12:645563. doi: 10.3389/fendo.2021.645563. Erratum in: *Front Endocrinol (Lausanne).* 2021 Nov 10;12:786732. doi: 10.3389/fendo.2021.786732. PMID: 34305810; PMCID: PMC8294388.

【25】 Alhomoud IS, Talasaz AH, Chandrasekaran P, Brown R, Mehta A, Dixon DL. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management. *Pharmacotherapy.* 2024 Sep 3. doi: 10.1002/phar.4607. Epub ahead of print. PMID: 39225417.

【26】 Valenzano A, Tartaglia N, Ambrosi A, Tafuri D, Monda M, Messina A, Sessa F, Campanozzi A, Monda V, Cibelli G, Messina G, Polito R. The Metabolic Rearrangements of Bariatric Surgery: Focus on Orexin-A and the Adiponectin System. *J Clin Med.* 2020 Oct 16;9(10):3327. doi: 10.3390/jcm9103327. PMID: 33081283; PMCID: PMC7602946.

【27】 Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, Kushner RF, Daniels SR, Wadden TA, Tsai AG, Hu FB, Jakicic JM, Ryan DH, Wolfe BM, Inge TH. The Science of Obesity Management: An Endocrine Society Scientific Statement. *Endocr Rev.* 2018 Apr 1;39(2):79-132. doi: 10.1210/er.2017-00253. PMID: 29518206; PMCID: PMC5888222.

【28】 Hadeifi A, Huberty V, Lemmers A, Arvanitakis M, Maggs D, Costamagna G, Devière J. Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes. *Dig Dis.* 2018;36(4):322-324. doi: 10.1159/000487078. Epub 2018 Apr 20. PMID: 29680836.

【29】 Murtha JA, Alagoz E, Breuer CR, Finn A, Raffa SD, Voils CI, Funk LM. Individual-level barriers to bariatric surgery from patient and provider perspectives: A

qualitative study. *Am J Surg.* 2022 Jul;224(1 Pt B):429-436. doi: 10.1016/j.amjsurg.2021.12.022. Epub 2021 Dec 23. PMID: 34963509; PMCID: PMC9218004.

【30】 Gagnon C, Schafer AL. Bone Health After Bariatric Surgery. *JBMR Plus.* 2018 May 1;2(3):121-133. doi: 10.1002/jbm4.10048. PMID: 30283897; PMCID: PMC6124196.

【31】 van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management. *Obes Rev.* 2017 Jan;18(1):68-85. doi: 10.1111/obr.12467. Epub 2016 Oct 17. PMID: 27749997.

【32】 Chakhtoura MT, Nakhoul NF, Akl EA, Safadi BY, Mantzoros CS, Metzendorf MI, El-Hajj Fuleihan G. Oral vitamin D supplementation for adults with obesity undergoing bariatric surgery. *Cochrane Database Syst Rev.* 2024 Oct 1;10(10):CD011800. doi: 10.1002/14651858.CD011800.pub2. PMID: 39351881; PMCID: PMC11443589.

【33】 Yadlapati S, Sánchez-Luna SA, Gromski MA, Mulki R. Managing the Bariatric Surgery Patient: Presurgery and Postsurgery Considerations. *Gastrointest Endosc Clin N Am.* 2024 Oct;34(4):627-638. doi: 10.1016/j.giec.2024.04.002. Epub 2024 May 4. PMID: 39277295.

【34】 Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev.* 2018 Nov 3;11(11):CD001484. doi: 10.1002/14651858.CD001484.pub4. PMID: 30390397; PMCID: PMC6477662.

【35】 Hirasawa N, Shimizu Y, Haginoya A, Soma Y, Watanabe G, Takehara K, Tokeji K, Mataka Y, Ishii R, Hada Y. Comparative Analysis of Muscle Activity and Circulatory Dynamics: A Crossover Study Using Leg Exercise Apparatus and Ergometer. *Medicina (Kaunas).* 2024 Aug 3;60(8):1260. doi: 10.3390/medicina60081260. PMID: 39202541; PMCID: PMC11356405.

【36】 Kang X, Zurita-Macias L, Hong D, Cadeddu M, Anvari M, Gmora S. A comparison of 30-day versus 90-day proton pump inhibitor therapy in prevention of

marginal ulcers after laparoscopic Roux-en-Y gastric bypass. *Surg Obes Relat Dis.* 2016 Jun;12(5):1003-1007. doi: 10.1016/j.soard.2015.11.010. Epub 2015 Nov 19. PMID: 26948448.

【37】 Wennerlund J, Gunnarsson U, Strigård K, Sundbom M. Acid-related complications after laparoscopic Roux-en-Y gastric bypass: risk factors and impact of proton pump inhibitors. *Surg Obes Relat Dis.* 2020 May;16(5):620-625. doi: 10.1016/j.soard.2020.01.005. Epub 2020 Jan 20. PMID: 32107170.

【38】 Choi JS, Kim JH, Ali MY, Min BS, Kim GD, Jung HA. Coptis chinensis alkaloids exert anti-adipogenic activity on 3T3-L1 adipocytes by downregulating C/EBP- α and PPAR- γ . *Fitoterapia.* 2014 Oct;98:199-208. doi: 10.1016/j.fitote.2014.08.006. Epub 2014 Aug 12. PMID: 25128422.

【39】 Cicero AF, Baggioni A. Berberine and Its Role in Chronic Disease. *Adv Exp Med Biol.* 2016;928:27-45. doi: 10.1007/978-3-319-41334-1_2. PMID: 27671811.

【40】 Qiu F, Zhu Z, Kang N, Piao S, Qin G, Yao X. Isolation and identification of urinary metabolites of berberine in rats and humans. *Drug Metab Dispos.* 2008 Nov;36(11):2159-65. doi: 10.1124/dmd.108.021659. Epub 2008 Aug 14. PMID: 18703644.

【41】 Guo HH, Shen HR, Wang LL, Luo ZG, Zhang JL, Zhang HJ, Gao TL, Han YX, Jiang JD. Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases. *Biomed Pharmacother.* 2023 Jul;163:114754. doi: 10.1016/j.biopha.2023.114754. Epub 2023 Apr 23. PMID: 37094549.

【42】 An N, Zhang G, Li Y, Yuan C, Yang F, Zhang L, Gao Y, Xing Y. Promising Antioxidative Effect of Berberine in Cardiovascular Diseases. *Front Pharmacol.* 2022 Mar 7;13:865353. doi: 10.3389/fphar.2022.865353. PMID: 35321323; PMCID: PMC8936808.

【43】 Cole LK, Zhang M, Chen L, Sparagna GC, Vandel M, Xiang B, Dolinsky VW, Hatch GM. Supplemental Berberine in a High-Fat Diet Reduces Adiposity and Cardiac Dysfunction in Offspring of Mouse Dams with Gestational Diabetes Mellitus. *J Nutr.* 2021 Apr 8;151(4):892-901. doi: 10.1093/jn/nxaa408. PMID: 33484149.

【44】 Poullos E, Koukounari S, Psara E, Vasios GK, Sakarikou C, Giaginis C. Anti-obesity Properties of Phytochemicals: Highlighting their Molecular Mechanisms against Obesity. *Curr Med Chem.* 2024;31(1):25-61. doi: 10.2174/0929867330666230517124033. PMID: 37198988.

【45】 Han Y, Xiang Y, Shi Y, Tang X, Pan L, Gao J, Bi R, Lai X. Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment. *Evid Based Complement Alternat Med.* 2021 Aug 21;2021:9987097. doi: 10.1155/2021/9987097. PMID: 34471420; PMCID: PMC8405293.

【46】 Chen W, Miao YQ, Fan DJ, Yang SS, Lin X, Meng LK, Tang X. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal

absorption in rats. *AAPS PharmSciTech*. 2011 Jun;12(2):705-11. doi: 10.1208/s12249-011-9632-z. Epub 2011 Jun 3. PMID: 21637946; PMCID: PMC3134654.

【47】 Gupta M, Rumman M, Singh B, Mahdi AA, Pandey S. Berberine ameliorates glucocorticoid-induced hyperglycemia: an in vitro and in vivo study. *Naunyn Schmiedebergs Arch Pharmacol*. 2024 Mar;397(3):1647-1658. doi: 10.1007/s00210-023-02703-2. Epub 2023 Sep 14. PMID: 37704773.

【48】 Xu JH, Liu XZ, Pan W, Zou DJ. Berberine protects against diet-induced obesity through regulating metabolic endotoxemia and gut hormone levels. *Mol Med Rep*. 2017 May;15(5):2765-2787. doi: 10.3892/mmr.2017.6321. Epub 2017 Mar 14. PMID: 28447763; PMCID: PMC5428400.

【49】 Park HJ, Jung E, Shim I. Berberine for Appetite Suppressant and Prevention of Obesity. *Biomed Res Int*. 2020 Dec 12;2020:3891806. doi: 10.1155/2020/3891806. PMID: 33415147; PMCID: PMC7752296.

【50】 Wang M, Geng X, Li K, Wang Y, Duan X, Hou C, Zhao L, Zhou H, Zhao D. Berberine ameliorates mesenteric vascular dysfunction by modulating perivascular adipose tissue in diet-induced obese in rats. *BMC Complement Med Ther*. 2022 Jul 25;22(1):198. doi: 10.1186/s12906-022-03667-1. PMID: 35879716; PMCID: PMC9310483.

【51】 Yang YN, Wang QC, Xu W, Yu J, Zhang H, Wu C. The berberine-enriched gut commensal *Blautia producta* ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression. *Biomed Pharmacother*. 2022 Nov;155:113749. doi: 10.1016/j.biopha.2022.113749. Epub 2022 Sep 26. PMID: 36174380.

【52】 Sun S, Yang Y, Xiong R, Ni Y, Ma X, Hou M, Chen L, Xu Z, Chen L, Ji M. Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut. *Life Sci*. 2022 Dec 15;311(Pt A):121141. doi: 10.1016/j.lfs.2022.121141. Epub 2022 Oct 29. PMID: 36341914.

【53】 Wang H, Chen S, Tang Y, Nie K, Gao Y, Wang Z, Su H, Wu F, Gong J, Fang K, Dong H, Hu M. Berberine promotes lacteal junction zippering and ameliorates diet-induced obesity through the RhoA/ROCK signaling pathway. *Phytomedicine*. 2024 Feb;124:155268. doi: 10.1016/j.phymed.2023.155268. Epub 2023 Dec 7. PMID: 38176265.

【54】 Du J, Zhu Y, Yang X, Geng X, Xu Y, Zhang M, Zhang M. Berberine attenuates obesity-induced insulin resistance by inhibiting miR-27a secretion. *Diabet Med*. 2024 Jul;41(7):e15319. doi: 10.1111/dme.15319. Epub 2024 May 6. PMID: 38711201.

【55】 Hu Y, Ehli EA, Kittelsrud J, Ronan PJ, Munger K, Downey T, Bohlen K, Callahan L, Munson V, Jahnke M, Marshall LL, Nelson K, Huizenga P, Hansen R, Soundy TJ, Davies GE. Lipid-lowering effect of berberine in human subjects and rats. *Phytomedicine*. 2012 Jul 15;19(10):861-7. doi: 10.1016/j.phymed.2012.05.009. Epub 2012 Jun 26. PMID: 22739410.

【56】 Bandala C, Carro-Rodríguez J, Cárdenas-Rodríguez N, Peña-Montero I, Gómez-López M, Hernández-Roldán AP, Huerta-Cruz JC, Muñoz-González F,

Ignacio-Mejía I, Domínguez B, Lara-Padilla E. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. *Nutrients*. 2024 Jul 16;16(14):2284. doi: 10.3390/nu16142284. PMID: 39064727; PMCID: PMC11280467.

【57】 Gasmi A, Asghar F, Zafar S, Oliinyk P, Khavrona O, Lysiuk R, Peana M, Piscopo S, Antonyak H, Pen JJ, Lozynska I, Noor S, Lenchyk L, Muhammad A, Vladimirova I, Dub N, Antoniv O, Tsal O, Upyr T, Bjørklund G. Berberine: Pharmacological Features in Health, Disease and Aging. *Curr Med Chem*. 2024;31(10):1214-1234. doi: 10.2174/0929867330666230207112539. PMID: 36748808.

【58】 Li Z, Wang Y, Xu Q, Ma J, Li X, Yan J, Tian Y, Wen Y, Chen T. Berberine and health outcomes: An umbrella review. *Phytother Res*. 2023 May;37(5):2051-2066. doi: 10.1002/ptr.7806. Epub 2023 Mar 31. PMID: 36999891.

【59】 Cui M, Li Y, Zheng T, Chen H, Wang J, Feng Y, Ye H, Dong Z, Li G. Efficacy and Molecular Mechanism of Quercetin on Constipation Induced by Berberine via Regulating Gut Microbiota. *Int J Mol Sci*. 2024 Jun 5;25(11):6228. doi: 10.3390/ijms25116228. PMID: 38892414; PMCID: PMC11173111.

【60】 Rosen ED. The transcriptional basis of adipocyte development. *Prostaglandins Leukot Essent Fatty Acids*. 2005 Jul;73(1):31-4. doi: 10.1016/j.plefa.2005.04.004. PMID: 15936931.

【61】 Wu YL, Lin H, Li HF, Don MJ, King PC, Chen HH. Salvia miltiorrhiza Extract and Individual Synthesized Component Derivatives Induce Activating-Transcription-Factor-3-Mediated Anti-Obesity Effects and Attenuate Obesity-Induced Metabolic Disorder by Suppressing C/EBP α in High-Fat-Induced Obese Mice. *Cells*. 2022 Mar 17;11(6):1022. doi: 10.3390/cells11061022. PMID: 35326476; PMCID: PMC8947163.

【62】 Lodhi IJ, Yin L, Jensen-Urstad AP, Funai K, Coleman T, Baird JH, El Ramahi MK, Razani B, Song H, Fu-Hsu F, Turk J, Semenkovich CF. Inhibiting adipose tissue lipogenesis reprograms thermogenesis and PPAR γ activation to decrease diet-induced obesity. *Cell Metab*. 2012 Aug 8;16(2):189-201. doi: 10.1016/j.cmet.2012.06.013. PMID: 22863804; PMCID: PMC3467338.

【63】 Freytag SO, Paielli DL, Gilbert JD. Ectopic expression of the CCAAT/enhancer-binding protein alpha promotes the adipogenic program in a variety of mouse fibroblastic cells. *Genes Dev*. 1994 Jul 15;8(14):1654-63. doi: 10.1101/gad.8.14.1654. PMID: 7958846.

【64】 Farmer SR. Transcriptional control of adipocyte formation. *Cell Metab*. 2006 Oct;4(4):263-73. doi: 10.1016/j.cmet.2006.07.001. PMID: 17011499; PMCID: PMC1958996.

【65】 Kajimura S, Seale P, Tomaru T, Erdjument-Bromage H, Cooper MP, Ruas JL, Chin S, Tempst P, Lazar MA, Spiegelman BM. Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. *Genes Dev*. 2008 May 15;22(10):1397-409. doi: 10.1101/gad.1666108. PMID: 18483224; PMCID: PMC2377193.

【66】 Payne VA, Au WS, Lowe CE, Rahman SM, Friedman JE, O'Rahilly S, Rochford JJ. C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis. *Biochem J*. 2009 Dec 14;425(1):215-23. doi: 10.1042/BJ20091112. PMID: 19811452; PMCID: PMC2913385.

【67】 Banerjee SS, Feinberg MW, Watanabe M, Gray S, Haspel RL, Denking DJ, Kawahara R, Hauner H, Jain MK. The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. *J Biol Chem*. 2003 Jan 24;278(4):2581-4. doi: 10.1074/jbc.M210859200. Epub 2002 Nov 7. PMID: 12426306.

【68】 Shou JW, Shaw PC. Berberine Reduces Lipid Accumulation in Obesity via Mediating Transcriptional Function of PPAR δ . *Int J Mol Sci*. 2023 Jul 18;24(14):11600. doi: 10.3390/ijms241411600. PMID: 37511356; PMCID: PMC10380538.

【69】 Zhang JW, Klemm DJ, Vinson C, Lane MD. Role of CREB in transcriptional regulation of CCAAT/enhancer-binding protein beta gene during adipogenesis. *J Biol Chem*. 2004 Feb 6;279(6):4471-8. doi: 10.1074/jbc.M311327200. Epub 2003 Oct 30. PMID: 14593102.

【70】 Yang DC, Tsay HJ, Lin SY, Chiou SH, Li MJ, Chang TJ, Hung SC. cAMP/PKA regulates osteogenesis, adipogenesis and ratio of RANKL/OPG mRNA expression in mesenchymal stem cells by suppressing leptin. *PLoS One*. 2008 Feb 6;3(2):e1540. doi: 10.1371/journal.pone.0001540. PMID: 18253488; PMCID: PMC2212109.

【71】 Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: an emerging all-out player in metabolic disorders and their complications. *Glycobiology*. 2015 Feb;25(2):136-50. doi: 10.1093/glycob/cwu111. Epub 2014 Oct 9. PMID: 25303959.

【72】 Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. *Obesity (Silver Spring)*. 2007 Jan;15(1):32-9. doi: 10.1038/oby.2007.526. PMID: 17228029.

【73】 Krautbauer S, Eisinger K, Hader Y, Buechler C. Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice. *Cytokine*. 2014 Oct;69(2):263-71. doi: 10.1016/j.cyto.2014.06.016. Epub 2014 Jul 17. PMID: 25043674.

【74】 Blasetti Fantauzzi C, Iacobini C, Menini S, Vitale M, Sorice GP, Mezza T, Cinti S, Giaccari A, Pugliese G. Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis. *Sci Rep*. 2020 Nov 18;10(1):20070. doi: 10.1038/s41598-020-76952-z. PMID: 33208796; PMCID: PMC7675972.

【75】 Florido R, Kwak L, Echouffo-Tcheugui JB, Zhang S, Michos ED, Nambi V, Goldberg RB, Hoogeveen RC, Lazo M, Gerstenblith G, Post WS, Blumenthal RS, Coresh J, Folsom AR, Selvin E, Ballantyne C, Ndumele CE. Obesity, Galectin-3, and Incident Heart Failure: The ARIC Study. *J Am Heart Assoc*. 2022 May 3;11(9):e023238. doi: 10.1161/JAHA.121.023238. Epub 2022 May 2. PMID: 35491999; PMCID: PMC9238585.

【76】 San Martín A, Du P, Dikalova A, Lassègue B, Aleman M, Góngora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. *Am J Physiol Heart Circ Physiol*. 2007 May;292(5):H2073-82. doi: 10.1152/ajpheart.00943.2006. Epub 2007 Jan 19. PMID: 17237245.

【77】 Thompson JA, Larion S, Mintz JD, Belin de Chantemèle EJ, Fulton DJ, Stepp DW. Genetic Deletion of NADPH Oxidase 1 Rescues Microvascular Function in Mice With Metabolic Disease. *Circ Res*. 2017 Aug 18;121(5):502-511. doi: 10.1161/CIRCRESAHA.116.309965. Epub 2017 Jul 6. PMID: 28684629; PMCID: PMC5729041.

【78】 Muñoz M, López-Oliva ME, Rodríguez C, Martínez MP, Sáenz-Medina J, Sánchez A, Climent B, Benedito S, García-Sacristán A, Rivera L, Hernández M, Prieto D. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity. *Redox Biol*. 2020 Jan;28:101330. doi: 10.1016/j.redox.2019.101330. Epub 2019 Sep 20. PMID: 31563085; PMCID: PMC6812001.

【79】 Gimenez M, Schickling BM, Lopes LR, Miller FJ Jr. Nox1 in cardiovascular diseases: regulation and pathophysiology. *Clin Sci (Lond)*. 2016 Feb;130(3):151-65. doi: 10.1042/CS20150404. PMID: 26678171.

【80】 Padgett CA, Bátori RK, Speese AC, Rosewater CL, Bush WB, Derella CC, Haigh SB, Sellers HG, Corley ZL, West MA, Mintz JD, Ange BB, Harris RA, Brands MW, Fulton DJR, Stepp DW. Galectin-3 Mediates Vascular Dysfunction in Obesity by Regulating NADPH Oxidase 1. *Arterioscler Thromb Vasc Biol*. 2023 Oct;43(10):e381-e395. doi: 10.1161/ATVBAHA.123.319476. Epub 2023 Aug 10. PMID: 37586054; PMCID: PMC10695282.

【81】 Uezumi A, Fukada S, Yamamoto N, Ikemoto-Uezumi M, Nakatani M, Morita M, Yamaguchi A, Yamada H, Nishino I, Hamada Y, Tsuchida K. Identification and characterization of PDGFR α + mesenchymal progenitors in human skeletal muscle. *Cell Death Dis*. 2014 Apr 17;5(4):e1186. doi: 10.1038/cddis.2014.161. PMID: 24743741; PMCID: PMC4001314.

【82】 Takada N, Takasugi M, Nonaka Y, Kamiya T, Takemura K, Satoh J, Ito S, Fujimoto K, Uematsu S, Yoshida K, Morita T, Nakamura H, Uezumi A, Ohtani N. Galectin-3 promotes the adipogenic differentiation of PDGFR α + cells and ectopic

fat formation in regenerating muscle. *Development*. 2022 Feb 1;149(3):dev199443. doi: 10.1242/dev.199443. Epub 2022 Feb 3. PMID: 35029658.

【83】 Baek JH, Kim SJ, Kang HG, Lee HW, Kim JH, Hwang KA, Song J, Chun KH. Galectin-3 activates PPAR γ and supports white adipose tissue formation and high-fat diet-induced obesity. *Endocrinology*. 2015 Jan;156(1):147-56. doi: 10.1210/en.2014-1374. PMID: 25343273.

【84】 Zhang J, Tang H, Deng R, Wang N, Zhang Y, Wang Y, Liu Y, Li F, Wang X, Zhou L. Berberine Suppresses Adipocyte Differentiation via Decreasing CREB Transcriptional Activity. *PLoS One*. 2015 Apr 30;10(4):e0125667. doi: 10.1371/journal.pone.0125667. PMID: 25928058; PMCID: PMC4415922.

【85】 Wang C, Wang Y, Ma SR, Zuo ZY, Wu YB, Kong WJ, Wang AP, Jiang JD. Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3. *Sci Rep*. 2019 Sep 16;9(1):13415. doi: 10.1038/s41598-019-50103-5. PMID: 31527742; PMCID: PMC6746795.

【86】 Utami AR, Maksum IP, Deawati Y. Berberine and Its Study as an Antidiabetic Compound. *Biology (Basel)*. 2023 Jul 8;12(7):973. doi: 10.3390/biology12070973. PMID: 37508403; PMCID: PMC10376565.

【87】 Chuang TY, Wu HL, Min J, Diamond M, Azziz R, Chen YH. Berberine regulates the protein expression of multiple tumorigenesis-related genes in hepatocellular carcinoma cell lines. *Cancer Cell Int*. 2017 May 30;17:59. doi: 10.1186/s12935-017-0429-3. PMID: 28572744; PMCID: PMC5450260.

【88】 Liu D, Zhang Y, Liu Y, Hou L, Li S, Tian H, Zhao T. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway. *Exp Clin Endocrinol Diabetes*. 2018 Sep;126(8):513-520. doi: 10.1055/s-0043-125066. Epub 2018 Jan 24. PMID: 29365334.

【89】 Ye Y, Liu X, Wu N, Han Y, Wang J, Yu Y, Chen Q. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. *Front Pharmacol*. 2021 Apr 26;12:653887. doi: 10.3389/fphar.2021.653887. PMID: 33981233; PMCID: PMC8107691.

【90】 Qian S, Tang Y, Tang QQ. Adipose tissue plasticity and the pleiotropic roles of BMP signaling. *J Biol Chem*. 2021 Jan-Jun;296:100678. doi: 10.1016/j.jbc.2021.100678. Epub 2021 Apr 17. PMID: 33872596; PMCID: PMC8131923.

【91】 Bartelt A, Heeren J. Adipose tissue browning and metabolic health. *Nat Rev Endocrinol*. 2014 Jan;10(1):24-36. doi: 10.1038/nrendo.2013.204. Epub 2013 Oct 22. PMID: 24146030.

【92】 Pilkington AC, Paz HA, Wankhade UD. Beige Adipose Tissue Identification and Marker Specificity-Overview. *Front Endocrinol (Lausanne)*. 2021 Mar 12;12:599134. doi: 10.3389/fendo.2021.599134. PMID: 33776911; PMCID: PMC7996049.

【93】 Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA, Nuutila P, Schaart G, Huang K, Tu H, van Marken Lichtenbelt WD,

Hoeks J, Enerbäck S, Schrauwen P, Spiegelman BM. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell*. 2012 Jul 20;150(2):366-76. doi: 10.1016/j.cell.2012.05.016. Epub 2012 Jul 12. PMID: 22796012; PMCID: PMC3402601.

【94】 Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. *Am J Physiol Cell Physiol*. 2000 Sep;279(3):C670-81. doi: 10.1152/ajpcell.2000.279.3.C670. PMID: 10942717.

【95】 Barbatelli G, Murano I, Madsen L, Hao Q, Jimenez M, Kristiansen K, Giacobino JP, De Matteis R, Cinti S. The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. *Am J Physiol Endocrinol Metab*. 2010 Jun;298(6):E1244-53. doi: 10.1152/ajpendo.00600.2009. Epub 2010 Mar 30. PMID: 20354155.

【96】 Nicholls DG, Locke RM. Thermogenic mechanisms in brown fat. *Physiol Rev*. 1984 Jan;64(1):1-64. doi: 10.1152/physrev.1984.64.1.1. PMID: 6320232.

【97】 Gong D, Lei J, He X, Hao J, Zhang F, Huang X, Gu W, Yang X, Yu J. Keys to the switch of fat burning: stimuli that trigger the uncoupling protein 1 (UCP1) activation in adipose tissue. *Lipids Health Dis*. 2024 Sep 28;23(1):322. doi: 10.1186/s12944-024-02300-z. PMID: 39342273; PMCID: PMC11439242.

【98】 Kim S, Park DH, Moon S, Gu B, Mantik KEK, Kwak HB, Ryu JK, Kang JH. Ketogenic diet with aerobic exercise can induce fat browning: potential roles of β -hydroxybutyrate. *Front Nutr*. 2024 Aug 29;11:1443483. doi: 10.3389/fnut.2024.1443483. PMID: 39267855; PMCID: PMC11390540.

【99】 Wang CH, Tsuji T, Wu LH, Yang CY, Huang TL, Sato M, Shamsi F, Tseng YH. Endothelin 3/EDNRB signaling induces thermogenic differentiation of white adipose tissue. *Nat Commun*. 2024 Aug 22;15(1):7215. doi: 10.1038/s41467-024-51579-0. PMID: 39174539; PMCID: PMC11341701.

【100】 Neira G, Hernández-Pardos AW, Becerril S, Ramírez B, Valentí V, Moncada R, Catalán V, Gómez-Ambrosi J, Burrell MA, Silva C, Escalada J, Frühbeck G, Rodríguez A. Differential mitochondrial adaptation and FNDC5 production in brown and white adipose tissue in response to cold and obesity. *Obesity (Silver Spring)*. 2024 Sep 26. doi: 10.1002/oby.24132. Epub ahead of print. PMID: 39327772.

【101】 Wang B, Hu Z, Cui L, Zhao M, Su Z, Jiang Y, Liu J, Zhao Y, Hou Y, Yang X, Zhang C, Guo B, Li D, Zhao L, Zheng S, Zhao Y, Yang W, Wang D, Yu S, Zhu S, Yan Y, Yuan G, Li K, Zhang W, Qin L, Zhang W, Sun F, Luo J, Zheng R. β AR-mTOR-lipin1 pathway mediates PKA-RII β deficiency-induced adipose browning. *Theranostics*. 2024 Aug 26;14(13):5316-5335. doi: 10.7150/thno.97046. PMID: 39267778; PMCID: PMC11388065.

【102】 Zhou WY, Liu P, Xia YF, Shi YJ, Xu HY, Ding M, Yang QQ, Qian SW, Tang Y, Lu Y, Tang QQ, Liu Y. NR2F6 is essential for brown adipocyte

differentiation and systemic metabolic homeostasis. *Mol Metab.* 2024 Mar;81:101891. doi: 10.1016/j.molmet.2024.101891. Epub 2024 Feb 1. PMID: 38307386; PMCID: PMC10864868.

【103】 Zhang Z, Zhang H, Li B, Meng X, Wang J, Zhang Y, Yao S, Ma Q, Jin L, Yang J, Wang W, Ning G. Berberine activates thermogenesis in white and brown adipose tissue. *Nat Commun.* 2014 Nov 25;5:5493. doi: 10.1038/ncomms6493. PMID: 25423280.

【104】 Ferdous MR, Abdalla M, Yang M, Xiaoling L, Song Y. Berberine chloride (dual topoisomerase I and II inhibitor) modulate mitochondrial uncoupling protein (UCP1) in molecular docking and dynamic with in-vitro cytotoxic and mitochondrial ATP production. *J Biomol Struct Dyn.* 2023 Mar;41(5):1704-1714. doi: 10.1080/07391102.2021.2024255. Epub 2022 May 25. PMID: 35612892.

【105】 Yao S, Yuan Y, Zhang H, Meng X, Jin L, Yang J, Wang W, Ning G, Zhang Y, Zhang Z. Berberine attenuates the abnormal ectopic lipid deposition in skeletal muscle. *Free Radic Biol Med.* 2020 Nov 1;159:66-75. doi: 10.1016/j.freeradbiomed.2020.07.028. Epub 2020 Jul 31. PMID: 32745766.

【106】 Wu L, Xia M, Duan Y, Zhang L, Jiang H, Hu X, Yan H, Zhang Y, Gu Y, Shi H, Li J, Gao X, Li J. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. *Cell Death Dis.* 2019 Jun 13;10(6):468. doi: 10.1038/s41419-019-1706-y. PMID: 31197160; PMCID: PMC6565685.

【107】 Sun Y, Xia M, Yan H, Han Y, Zhang F, Hu Z, Cui A, Ma F, Liu Z, Gong Q, Chen X, Gao J, Bian H, Tan Y, Li Y, Gao X. Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21. *Br J Pharmacol.* 2018 Jan;175(2):374-387. doi: 10.1111/bph.14079. Epub 2017 Dec 15. PMID: 29065221; PMCID: PMC5758394.

【108】 Li C, Leng Q, Li L, Hu F, Xu Y, Gong S, Yang Y, Zhang H, Li X. Berberine Ameliorates Obesity by Inducing GDF15 Secretion by Brown Adipocytes. *Endocrinology.* 2023 Feb 11;164(4):bqad035. doi: 10.1210/endocr/bqad035. PMID: 36825874.

【109】 Karnjana K, Golaka R, Benjakul N, Chandee N. Correlation of vascular structural changes in a cadaveric model and obesity-related cardiovascular non-communicable diseases. *Cardiovasc Pathol.* 2022 Nov-Dec;61:107471. doi: 10.1016/j.carpath.2022.107471. Epub 2022 Aug 28. PMID: 36038052.

【110】 Rønn PF, Andersen GS, Lauritzen T, Christensen DL, Aadahl M, Carstensen B, Grarup N, Jørgensen ME. Abdominal visceral and subcutaneous adipose tissue and associations with cardiometabolic risk in Inuit, Africans and Europeans: a cross-sectional study. *BMJ Open.* 2020 Sep 14;10(9):e038071. doi: 10.1136/bmjopen-2020-038071. PMID: 32928857; PMCID: PMC7490939.

【111】 Yan Y, Liu J, Zhao X, Cheng H, Huang G, Mi J; China Child and Adolescent Cardiovascular Health study (CCACH) research group. Abdominal

visceral and subcutaneous adipose tissues in association with cardiometabolic risk in children and adolescents: the China Child and Adolescent Cardiovascular Health (CCACH) study. *BMJ Open Diabetes Res Care*. 2019 Dec 8;7(1):e000824. doi: 10.1136/bmjdr-2019-000824. PMID: 31875134; PMCID: PMC6904186.

【112】 Guan S, Wang B, Li W, Guan J, Fang X. Effects of berberine on expression of LOX-1 and SR-BI in human macrophage-derived foam cells induced by ox-LDL. *Am J Chin Med*. 2010;38(6):1161-9. doi: 10.1142/S0192415X10008548. PMID: 21061468.

【113】 Basatemur GL, Jørgensen HF, Clarke MCH, Bennett MR, Mallat Z. Vascular smooth muscle cells in atherosclerosis. *Nat Rev Cardiol*. 2019 Dec;16(12):727-744. doi: 10.1038/s41569-019-0227-9. Epub 2019 Jun 26. PMID: 31243391.

【114】 Wang TT, Yu LL, Zheng JM, Han XY, Jin BY, Hua CJ, Chen YS, Shang SS, Liang YZ, Wang JR. Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway. *Chin J Integr Med*. 2024 Oct;30(10):906-916. doi: 10.1007/s11655-024-3666-z. Epub 2024 Aug 21. PMID: 39167283.

【115】 Hong Y, Feng J, Dou Z, Sun X, Hu Y, Chen Z, Liu L, Xu H, Du M, Tang P, Liu X, Zhang Y. Berberine as a novel ACSL4 inhibitor to suppress endothelial ferroptosis and atherosclerosis. *Biomed Pharmacother*. 2024 Aug;177:117081. doi: 10.1016/j.biopha.2024.117081. Epub 2024 Jul 5. PMID: 38971008.

【116】 Zwick RK, Guerrero-Juarez CF, Horsley V, Plikus MV. Anatomical, Physiological, and Functional Diversity of Adipose Tissue. *Cell Metab*. 2018 Jan 9;27(1):68-83. doi: 10.1016/j.cmet.2017.12.002. PMID: 29320711; PMCID: PMC6050204.

【117】 Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. *Front Physiol*. 2020 Oct 30;11:578966. doi: 10.3389/fphys.2020.578966. PMID: 33192583; PMCID: PMC7662468.

【118】 Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, Wang S, Wu J, Wang Y, Li Z, Liu J, Jiang JD. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nat Med*. 2004 Dec;10(12):1344-51. doi: 10.1038/nm1135. Epub 2004 Nov 7. PMID: 15531889.

【119】 Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation. *Arzneimittelforschung*. 2007;57(1):26-30. doi: 10.1055/s-0031-1296582. PMID: 17341006.

【120】 Li Z, Jiang JD, Kong WJ. Berberine up-regulates hepatic low-density lipoprotein receptor through Ras-independent but AMP-activated protein kinase-dependent Raf-1 activation. *Biol Pharm Bull.* 2014;37(11):1766-75. doi: 10.1248/bpb.b14-00412. Epub 2014 Sep 5. PMID: 25196457.

【121】 Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. *Arterioscler Thromb Vasc Biol.* 2005 Oct;25(10):2170-6. doi: 10.1161/01.ATV.0000181761.16341.2b. Epub 2005 Aug 11. PMID: 16100034.

【122】 Singh AB, Li H, Kan CF, Dong B, Nicolls MR, Liu J. The critical role of mRNA destabilizing protein heterogeneous nuclear ribonucleoprotein d in 3' untranslated region-mediated decay of low-density lipoprotein receptor mRNA in liver tissue. *Arterioscler Thromb Vasc Biol.* 2014 Jan;34(1):8-16. doi: 10.1161/ATVBAHA.112.301131. Epub 2013 Oct 24. PMID: 24158514; PMCID: PMC4032120.

【123】 Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. *Biochem Biophys Res Commun.* 2007 Nov 3;362(4):853-7. doi: 10.1016/j.bbrc.2007.08.060. Epub 2007 Aug 27. Erratum in: *Biochem Biophys Res Commun.* 2008 Aug 15;373(1):176. PMID: 17767919.

【124】 Jia R, Hou Y, Zhang L, Li B, Zhu J. Effects of Berberine on Lipid Metabolism, Antioxidant Status, and Immune Response in Liver of Tilapia (*Oreochromis niloticus*) under a High-Fat Diet Feeding. *Antioxidants (Basel).* 2024 Apr 29;13(5):548. doi: 10.3390/antiox13050548. PMID: 38790653; PMCID: PMC11117941.

【125】 Sun R, Yang N, Kong B, Cao B, Feng D, Yu X, Ge C, Huang J, Shen J, Wang P, Feng S, Fei F, Guo J, He J, Aa N, Chen Q, Pan Y, Schumacher JD, Yang CS, Guo GL, Aa J, Wang G. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. *Mol Pharmacol.* 2017 Feb;91(2):110-122. doi: 10.1124/mol.116.106617. Epub 2016 Dec 8. PMID: 27932556; PMCID: PMC5267522.

【126】 DeBose-Boyd RA, Ye J. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond. *Trends Biochem Sci.* 2018 May;43(5):358-368. doi: 10.1016/j.tibs.2018.01.005. Epub 2018 Feb 27. PMID: 29500098; PMCID: PMC5923433.

【127】 Feng R, Zhao ZX, Ma SR, Guo F, Wang Y, Jiang JD. Gut Microbiota-Regulated Pharmacokinetics of Berberine and Active Metabolites in Beagle Dogs After Oral Administration. *Front Pharmacol.* 2018 Mar 21;9:214. doi: 10.3389/fphar.2018.00214. PMID: 29618977; PMCID: PMC5871679.

【128】 Ho YC, Srinivasan RS. Lymphatic Vasculature in Energy Homeostasis and Obesity. *Front Physiol.* 2020 Jan 22;11:3. doi: 10.3389/fphys.2020.00003. PMID: 32038308; PMCID: PMC6987243.

【129】 Zhang F, Zarkada G, Han J, Li J, Dubrac A, Ola R, Genet G, Boyé K, Michon P, Künzel SE, Camporez JP, Singh AK, Fong GH, Simons M, Tso P, Fernández-Hernando C, Shulman GI, Sessa WC, Eichmann A. Lacteal junction zipper protects against diet-induced obesity. *Science*. 2018 Aug 10;361(6402):599-603. doi: 10.1126/science.aap9331. PMID: 30093598; PMCID: PMC6317738.

【130】 Kang S, Li Z, Yin Z, Jia R, Song X, Li L, Chen Z, Peng L, Qu J, Hu Z, Lai X, Wang G, Liang X, He C, Yin L. The antibacterial mechanism of berberine against *Actinobacillus pleuropneumoniae*. *Nat Prod Res*. 2015;29(23):2203-6. doi: 10.1080/14786419.2014.1001388. Epub 2015 Jan 23. PMID: 25613587.

【131】 Jia Y, Hao C, Yang Q, Zhang W, Li G, Liu S, Hua X. Inhibition of *Haemophilus parasuis* by berberine and proteomic studies of its mechanism of action. *Res Vet Sci*. 2021 Sep;138:62-68. doi: 10.1016/j.rvsc.2021.06.004. Epub 2021 Jun 5. PMID: 34111715.

【132】 Peng L, Kang S, Yin Z, Jia R, Song X, Li L, Li Z, Zou Y, Liang X, Li L, He C, Ye G, Yin L, Shi F, Lv C, Jing B. Antibacterial activity and mechanism of berberine against *Streptococcus agalactiae*. *Int J Clin Exp Pathol*. 2015 May 1;8(5):5217-23. PMID: 26191220; PMCID: PMC4503092.

【133】 Ye F, Zhou Q, Tian L, Lei F, Feng D. The protective effect of berberine hydrochloride on LPS-induced osteoclastogenesis through inhibiting TRAF6-Ca²⁺-calcineurin-NFATc1 signaling pathway. *Mol Med Rep*. 2017 Nov;16(5):6228-6233. doi: 10.3892/mmr.2017.7338. Epub 2017 Aug 23. PMID: 28849049.

【134】 Wang Y, Shou JW, Li XY, Zhao ZX, Fu J, He CY, Feng R, Ma C, Wen BY, Guo F, Yang XY, Han YX, Wang LL, Tong Q, You XF, Lin Y, Kong WJ, Si SY, Jiang JD. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. *Metabolism*. 2017 May;70:72-84. doi: 10.1016/j.metabol.2017.02.003. Epub 2017 Feb 10. PMID: 28403947.

【135】 Gao Z, Li Q, Wu X, Zhao X, Zhao L, Tong X. New Insights into the Mechanisms of Chinese Herbal Products on Diabetes: A Focus on the "Bacteria-Mucosal Immunity-Inflammation-Diabetes" Axis. *J Immunol Res*. 2017;2017:1813086. doi: 10.1155/2017/1813086. Epub 2017 Oct 15. PMID: 29164155; PMCID: PMC5661076.

【136】 Xie W, Gu D, Li J, Cui K, Zhang Y. Effects and action mechanisms of berberine and *Rhizoma coptidis* on gut microbes and obesity in high-fat diet-fed C57BL/6J mice. *PLoS One*. 2011;6(9):e24520. doi: 10.1371/journal.pone.0024520. Epub 2011 Sep 6. PMID: 21915347; PMCID: PMC3167861.

【137】 Wu C, Zhao Y, Zhang Y, Yang Y, Su W, Yang Y, Sun L, Zhang F, Yu J, Wang Y, Guo P, Zhu B, Wu S. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's

cholesterol-decreasing efficacy in patients. *J Adv Res.* 2021 Jul 30;37:197-208. doi: 10.1016/j.jare.2021.07.011. PMID: 35499044; PMCID: PMC9039652.

【138】 Sun H, Wang N, Cang Z, Zhu C, Zhao L, Nie X, Cheng J, Xia F, Zhai H, Lu Y. Modulation of Microbiota-Gut-Brain Axis by Berberine Resulting in Improved Metabolic Status in High-Fat Diet-Fed Rats. *Obes Facts.* 2016;9(6):365-378. doi: 10.1159/000449507. Epub 2016 Nov 30. PMID: 27898425; PMCID: PMC5644798.

【139】 Yang WL, Zhang CY, Ji WY, Zhao LL, Yang FY, Zhang L, Cao X. Berberine Metabolites Stimulate GLP-1 Secretion by Alleviating Oxidative Stress and Mitochondrial Dysfunction. *Am J Chin Med.* 2024;52(1):253-274. doi: 10.1142/S0192415X24500113. Epub 2024 Feb 8. PMID: 38351702.

【140】 Wang H, Zhang H, Gao Z, Zhang Q, Gu C. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. *Front Cell Infect Microbiol.* 2022 Aug 25;12:854885. doi: 10.3389/fcimb.2022.854885. PMID: 36093200; PMCID: PMC9452888.

【141】 Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from *Akkermansia muciniphila* or the pasteurized bacterium improves metabolism in obese and diabetic mice. *Nat Med.* 2017 Jan;23(1):107-113. doi: 10.1038/nm.4236. Epub 2016 Nov 28. PMID: 27892954.

【142】 Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A.* 2013 May 28;110(22):9066-71. doi: 10.1073/pnas.1219451110. Epub 2013 May 13. PMID: 23671105; PMCID: PMC3670398.

【143】 Chen Y, Hao Z, Zhao H, Duan X, Jia D, Li K, Yang Y, Cui H, Gao M, Zhao D. Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan metabolites. *J Sci Food Agric.* 2023 Feb;103(3):1464-1473. doi: 10.1002/jsfa.12242. Epub 2022 Oct 10. PMID: 36168925.

【144】 Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. *Med Sci Monit.* 2011 Jul;17(7):RA164-7. doi: 10.12659/msm.881842. PMID: 21709646; PMCID: PMC3539561.

【145】 Sunwoo JY, Eliasberg CD, Carballo CB, Rodeo SA. The role of the macrophage in tendinopathy and tendon healing. *J Orthop Res.* 2020 Aug;38(8):1666-1675. doi: 10.1002/jor.24667. Epub 2020 Mar 30. PMID: 32190920.

【146】 Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest.* 2003 Dec;112(12):1796-808. doi: 10.1172/JCI19246. PMID: 14679176; PMCID: PMC296995.

【147】 Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J Clin Invest*. 2007 Jan;117(1):175-84. doi: 10.1172/JCI29881. PMID: 17200717; PMCID: PMC1716210.

【148】 Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. *Diabetes*. 2007 Jan;56(1):16-23. doi: 10.2337/db06-1076. PMID: 17192460.

【149】 Russo L, Lumeng CN. Properties and functions of adipose tissue macrophages in obesity. *Immunology*. 2018 Dec;155(4):407-417. doi: 10.1111/imm.13002. Epub 2018 Oct 19. PMID: 30229891; PMCID: PMC6230999.

【150】 Noh JW, Jun MS, Yang HK, Lee BC. Cellular and Molecular Mechanisms and Effects of Berberine on Obesity-Induced Inflammation. *Biomedicines*. 2022 Jul 19;10(7):1739. doi: 10.3390/biomedicines10071739. PMID: 35885044; PMCID: PMC9312506.

【151】 Gong S, Chen J, Zheng X, Lu X, Chen M, Li J, Su Z, Liu Y, Chen J, Xie J, Xie Q, Li Y. Kidney targeting and modulating macrophage polarization through AMPK signaling: Therapeutic mechanism of berberine in uric acid nephropathy. *Int Immunopharmacol*. 2024 Sep 10;138:112632. doi: 10.1016/j.intimp.2024.112632. Epub 2024 Jul 9. PMID: 38986300.

【152】 Wu H, Zhang L, Dong X, Yang J, Zheng L, Li L, Liu X, Jin M, Zhang P. Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy. *Biomed Pharmacother*. 2024 Sep;178:117135. doi: 10.1016/j.biopha.2024.117135. Epub 2024 Jul 23. PMID: 39047421.

【153】 Lin J, Cai Q, Liang B, Wu L, Zhuang Y, He Y, Lin W. Berberine, a Traditional Chinese Medicine, Reduces Inflammation in Adipose Tissue, Polarizes M2 Macrophages, and Increases Energy Expenditure in Mice Fed a High-Fat Diet. *Med Sci Monit*. 2019 Jan 4;25:87-97. doi: 10.12659/MSM.911849. PMID: 30606998; PMCID: PMC6330261.

【154】 Geeraerts X, Bolli E, Fendt SM, Van Ginderachter JA. Macrophage Metabolism As Therapeutic Target for Cancer, Atherosclerosis, and Obesity. *Front Immunol*. 2017 Mar 15;8:289. doi: 10.3389/fimmu.2017.00289. PMID: 28360914; PMCID: PMC5350105.

【155】 Zhang S, Xu P, Zhu Z, Zhou L, Li J, Zhou R, Kan Y, Li Y, Yu X, Zhao J, Jin Y, Yan J, Fang P, Shang W. Acetylation of p65Lys310 by p300 in macrophages mediates anti-inflammatory property of berberine. *Redox Biol*. 2023 Jun;62:102704. doi: 10.1016/j.redox.2023.102704. Epub 2023 Apr 17. PMID: 37086629; PMCID: PMC10172918.

【156】 Zhou H, Feng L, Xu F, Sun Y, Ma Y, Zhang X, Liu H, Xu G, Wu X, Shen Y, Sun Y, Wu X, Xu Q. Berberine inhibits palmitate-induced NLRP3 inflammasome activation by triggering autophagy in macrophages: A new mechanism linking berberine to insulin resistance improvement. *Biomed Pharmacother*. 2017 May;89:864-874. doi: 10.1016/j.biopha.2017.03.003. Epub 2017 Mar 6. PMID: 28282788.

【157】 Zhang XY, Yu L, Wang K, Wang M, Li P, Zheng ZG, Yang H. The combination of berberine and isoliquiritigenin synergistically improved adipose inflammation and obesity-induced insulin resistance. *Phytother Res.* 2024 Aug;38(8):3839-3855. doi: 10.1002/ptr.8233. Epub 2024 May 10. PMID: 38729776.

【158】 He W, Kapate N, Shields CW 4th, Mitragotri S. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. *Adv Drug Deliv Rev.* 2020;165-166:15-40. doi: 10.1016/j.addr.2019.12.001. Epub 2019 Dec 6. PMID: 31816357.

【159】 Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. *Semin Immunol.* 2015 Aug;27(4):249-56. doi: 10.1016/j.smim.2015.07.003. Epub 2015 Aug 22. PMID: 26303100.

【160】 Li D, Yang C, Zhu JZ, Lopez E, Zhang T, Tong Q, Peng C, Lin LG. Berberine remodels adipose tissue to attenuate metabolic disorders by activating sirtuin 3. *Acta Pharmacol Sin.* 2022 May;43(5):1285-1298. doi: 10.1038/s41401-021-00736-y. Epub 2021 Aug 20. PMID: 34417576; PMCID: PMC9061715.

【161】 Sun J, Zeng Q, Wu Z, Huang L, Sun T, Ling C, Zhang B, Chen C, Wang H. Berberine inhibits NLRP3 inflammasome activation and proinflammatory macrophage M1 polarization to accelerate peripheral nerve regeneration. *Neurotherapeutics.* 2024 Jul;21(4):e00347. doi: 10.1016/j.neurot.2024.e00347. Epub 2024 Apr 3. PMID: 38570276; PMCID: PMC11067341.

【162】 Kwon S, Seok S, Yau P, Li X, Kemper B, Kemper JK. Obesity and aging diminish sirtuin 1 (SIRT1)-mediated deacetylation of SIRT3, leading to hyperacetylation and decreased activity and stability of SIRT3. *J Biol Chem.* 2017 Oct 20;292(42):17312-17323. doi: 10.1074/jbc.M117.778720. Epub 2017 Aug 14. PMID: 28808064; PMCID: PMC5655509.

【163】 Meng G, Li P, Du X, Feng X, Qiu F. Berberine alleviates ulcerative colitis by inhibiting inflammation through targeting IRGM1. *Phytomedicine.* 2024 Oct;133:155909. doi: 10.1016/j.phymed.2024.155909. Epub 2024 Jul 23. PMID: 39068762.

【164】 Mansour A, Noori M, Hakemi MS, Haghgooyan Z, Mohajeri-Tehrani MR, Mirahmad M, Sajjadi-Jazi SM. Hyperandrogenism and anthropometric parameters in women with polycystic ovary syndrome. *BMC Endocr Disord.* 2024 Sep 27;24(1):201. doi: 10.1186/s12902-024-01733-y. PMID: 39333998; PMCID: PMC11438141.

【165】 Shorakae S, Teede H, de Courten B, Lambert G, Boyle J, Moran LJ. The Emerging Role of Chronic Low-Grade Inflammation in the Pathophysiology of Polycystic Ovary Syndrome. *Semin Reprod Med.* 2015 Jul;33(4):257-69. doi: 10.1055/s-0035-1556568. Epub 2015 Jul 1. PMID: 26132930.

【166】 Shen HR, Xu X, Li XL. Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis.

Reprod Biol Endocrinol. 2021 Jan 7;19(1):3. doi: 10.1186/s12958-020-00684-y. PMID: 33407557; PMCID: PMC7789273.

【167】 Urasaki Y, Le TT. Cinnamaldehyde and Curcumin Prime Akt2 for Insulin-Stimulated Activation. *Nutrients*. 2022 Aug 12;14(16):3301. doi: 10.3390/nu14163301. PMID: 36014807; PMCID: PMC9416494.

【168】 Urasaki Y, Le TT. A Composition of Phytonutrients for Glycemic and Weight Management. *Nutrients*. 2022 Sep 14;14(18):3784. doi: 10.3390/nu14183784. PMID: 36145160; PMCID: PMC9501537.

【169】 Yue SJ, Wang WX, Zhang L, Liu J, Feng WW, Gao H, Tang YP, Yan D. Anti-obesity and Gut Microbiota Modulation Effect of Astragalus Polysaccharides Combined with Berberine on High-Fat Diet-Fed Obese Mice. *Chin J Integr Med*. 2023 Jul;29(7):617-625. doi: 10.1007/s11655-021-3303-z. Epub 2021 Dec 18. PMID: 34921647.

【170】 Payab M, Hasani-Ranjbar S, Baeri M, Rahimifard M, Arjmand B, Haghi-Aminjan H, Abdollahi M, Larijani B. Development of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes. *Iran Biomed J*. 2020 May;24(3):155-63. doi: 10.29252/ibj.24.3.155. Epub 2019 Nov 30. PMID: 31952433; PMCID: PMC7275626.

【171】 Guarino G, Strollo F, Carbone L, Della Corte T, Letizia M, Marino G, Gentile S. Bioimpedance analysis, metabolic effects and safety of the association *Berberis aristata/Bilybum marianum*: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes. *J Biol Regul Homeost Agents*. 2017 Apr-Jun;31(2):495-502. PMID: 28685558.

【172】 Lin Q, Xing J, Liu Y Y, et al. taBOX: A water-soluble tetraanionic rectangular molecular container for conjugated molecules and taste masking for berberine and palmatine. *Chinese Chemical Letters*. 2024; 35(5): 109119.

【173】 Zhou L, Dodd S, Capacci-Daniel C, Garad S, Panicucci R, Sethuraman V. Co-crystal formation based on structural matching. *Eur J Pharm Sci*. 2016 Jun 10;88:191-201. doi: 10.1016/j.ejps.2016.02.017. Epub 2016 Mar 4. PMID: 26948852.

【174】 Fulas OA, Laferrière A, Ayoub G, Gandrath D, Mottillo C, Titi HM, Stein RS, Frišćić T, Coderre TJ. Drug-Nutraceutical Co-Crystal and Salts for Making New and Improved Bi-Functional Analgesics. *Pharmaceutics*. 2020 Nov 26;12(12):1144. doi: 10.3390/pharmaceutics12121144. PMID: 33255979; PMCID: PMC7761172.

【175】 Wang M, Xu R, Liu X, Zhang L, Qiu S, Lu Y, Zhang P, Yan M, Zhu J. A co-crystal berberine-ibuprofen improves obesity by inhibiting the protein kinases TBK1 and IKK ϵ . *Commun Biol*. 2022 Aug 12;5(1):807. doi: 10.1038/s42003-022-03776-0. PMID: 35962183; PMCID: PMC9374667.

【176】 Zhao P, Wong KI, Sun X, Reilly SM, Uhm M, Liao Z, Skorobogatko Y, Saltiel AR. TBK1 at the Crossroads of Inflammation and Energy Homeostasis in Adipose Tissue. *Cell*. 2018 Feb 8;172(4):731-743.e12. doi: 10.1016/j.cell.2018.01.007. PMID: 29425491; PMCID: PMC5808582.

【177】 Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma JT, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, Saltiel AR. The protein kinase IKKepsilon regulates energy balance in obese mice. *Cell*. 2009 Sep 4;138(5):961-75. doi: 10.1016/j.cell.2009.06.046. PMID: 19737522; PMCID: PMC2756060.

【178】 Hu CM, Zhang L, Aryal S, Cheung C, Fang RH, Zhang L. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. *Proc Natl Acad Sci U S A*. 2011 Jul 5;108(27):10980-5. doi: 10.1073/pnas.1106634108. Epub 2011 Jun 20. PMID: 21690347; PMCID: PMC3131364.

【179】 Xu H, Li S, Liu YS. Nanoparticles in the diagnosis and treatment of vascular aging and related diseases. *Signal Transduct Target Ther*. 2022 Jul 11;7(1):231. doi: 10.1038/s41392-022-01082-z. PMID: 35817770; PMCID: PMC9272665.

【180】 Hu CM, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, Nguyen P, Angsantikul P, Wen CH, Kroll AV, Carpenter C, Ramesh M, Qu V, Patel SH, Zhu J, Shi W, Hofman FM, Chen TC, Gao W, Zhang K, Chien S, Zhang L. Nanoparticle biointerfacing by platelet membrane cloaking. *Nature*. 2015 Oct 1;526(7571):118-21. doi: 10.1038/nature15373. Epub 2015 Sep 16. PMID: 26374997; PMCID: PMC4871317.

【181】 Piao JG, Wang L, Gao F, You YZ, Xiong Y, Yang L. Erythrocyte membrane is an alternative coating to polyethylene glycol for prolonging the circulation lifetime of gold nanocages for photothermal therapy. *ACS Nano*. 2014 Oct 28;8(10):10414-25. doi: 10.1021/nn503779d. Epub 2014 Oct 9. PMID: 25286086.

【182】 Liu Y, Luo J, Chen X, Liu W, Chen T. Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications. *Nanomicro Lett*. 2019 Nov 16;11(1):100. doi: 10.1007/s40820-019-0330-9. PMID: 34138027; PMCID: PMC7770915.

【183】 Rao L, Bu LL, Cai B, Xu JH, Li A, Zhang WF, Sun ZJ, Guo SS, Liu W, Wang TH, Zhao XZ. Cancer Cell Membrane-Coated Upconversion Nanoprobes for Highly Specific Tumor Imaging. *Adv Mater*. 2016 May;28(18):3460-6. doi: 10.1002/adma.201506086. Epub 2016 Mar 10. PMID: 26970518.

【184】 Xu HY, Liu CS, Huang CL, Chen L, Zheng YR, Huang SH, Long XY. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. *Colloids Surf B Biointerfaces*. 2019 Sep 1;181:927-934. doi: 10.1016/j.colsurfb.2019.06.006. Epub 2019 Jun 4. PMID: 31382342.

【185】 Mirhadi E, Rezaee M, Malaekheh-Nikouei B. Nano strategies for berberine delivery, a natural alkaloid of *Berberis*. *Biomed Pharmacother*. 2018 Aug;104:465-473. doi: 10.1016/j.biopha.2018.05.067. Epub 2018 May 25. PMID: 29793179.

【186】 Glassman PM, Villa CH, Ukidve A, Zhao Z, Smith P, Mitragotri S, Russell AJ, Brenner JS, Muzykantov VR. Vascular Drug Delivery Using Carrier Red

Blood Cells: Focus on RBC Surface Loading and Pharmacokinetics. *Pharmaceutics*. 2020 May 9;12(5):440. doi: 10.3390/pharmaceutics12050440. PMID: 32397513; PMCID: PMC7284780.

【187】 Aghili ZS, Mirzaei SA, Banitalebi-Dehkordi M. A potential hypothesis for 2019-nCoV infection therapy through delivery of recombinant ACE2 by red blood cell-hitchhiking. *J Biol Res (Thessalon)*. 2020 Dec 7;27:17. doi: 10.1186/s40709-020-00129-y. PMID: 34963881; PMCID: PMC7720268.

【188】 Aghili ZS, Magnani M, Ghatrehsamani M, Nourian Dehkordi A, Mirzaei SA, Banitalebi Dehkordi M. Intelligent berberine-loaded erythrocytes attenuated inflammatory cytokine productions in macrophages. *Sci Rep*. 2024 Apr 23;14(1):9381. doi: 10.1038/s41598-024-60103-9. PMID: 38654085; PMCID: PMC11039762.

【189】 Tang X, Shi Y, Chen Y, Sun Z, Wang L, Tang P, Cui H, Zhao W, Xu W, Kopylov P, Shchekochikhin D, Afina B, Han W, Liu X, Zhang Y. Tetrahydroberberubine exhibits preventive effect on obesity by activating PGC1 α -mediated thermogenesis in white and brown adipose tissue. *Biochem Pharmacol*. 2024 Aug;226:116381. doi: 10.1016/j.bcp.2024.116381. Epub 2024 Jun 21. PMID: 38909786.

【190】 Li QP, Dou YX, Huang ZW, Chen HB, Li YC, Chen JN, Liu YH, Huang XQ, Zeng HF, Yang XB, Su ZR, Xie JH. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. *Phytomedicine*. 2021 May;85:153550. doi: 10.1016/j.phymed.2021.153550. Epub 2021 Mar 17. PMID: 33831691.

【191】 Khvostov MV, Gladkova ED, Borisov SA, Fedotova MS, Zhukova NA, Marenina MK, Meshkova YV, Luzina OA, Tolstikova TG, Salakhutdinov NF. Study of Hypoglycemic Activity of Novel 9-N-alkyltetrahydroberberine Derivatives. *Int J Mol Sci*. 2022 Nov 16;23(22):14186. doi: 10.3390/ijms232214186. PMID: 36430664; PMCID: PMC9698964.

【192】 Khvostov MV, Gladkova ED, Borisov SA, Zhukova NA, Marenina MK, Meshkova YV, Luzina OA, Tolstikova TG, Salakhutdinov NF. Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action. *Pharmaceutics*. 2021 Dec 12;13(12):2138. doi: 10.3390/pharmaceutics13122138. PMID: 34959419; PMCID: PMC8708145.

【193】 Tan L, Wang Y, Ai G, Luo C, Chen H, Li C, Zeng H, Xie J, Chen J, Su Z. Dihydroberberine, a hydrogenated derivative of berberine firstly identified in *Phellodendri Chinese Cortex*, exerts anti-inflammatory effect via dual modulation of NF- κ B and MAPK signaling pathways. *Int Immunopharmacol*. 2019 Oct;75:105802. doi: 10.1016/j.intimp.2019.105802. Epub 2019 Aug 8. PMID: 31401380.

【194】 Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. *Nutrients*. 2021 Dec 28;14(1):124. doi: 10.3390/nu14010124. PMID: 35010998; PMCID: PMC8746601.

【195】 Teng Q, Zhu X, Guo Q, Jiang W, Liu J, Meng Q. Synthesis of 9-O-arylated berberines via copper-catalyzed CAr-O coupling reactions. *Beilstein J*

Org Chem. 2019 Jul 15;15:1575-1580. doi: 10.3762/bjoc.15.161. PMID: 31435439; PMCID: PMC6664384.

【196】 Cheng Z, Chen AF, Wu F, Sheng L, Zhang HK, Gu M, Li YY, Zhang LN, Hu LH, Li JY, Li J. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. *Bioorg Med Chem*. 2010 Aug 15;18(16):5915-24. doi: 10.1016/j.bmc.2010.06.085. Epub 2010 Jul 1. PMID: 20663675.